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SUMMARY 
 
Organ-specific autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, are 
driven by the conduct of auto-aggressive T helper cells. It has long been accepted that TH1 
cells are the major pathogenic cell population in autoimmune inflammation while TH2 cells 
are beneficial in what is known as the TH1/TH2 paradigm. However, recent data obtained in 
gene-targeted mice and the newly discovered TH17 phenotype have proved conflictive with 
this hypothesis and have provoked a paradigm shift. It is thus becoming widely accepted that 
TH1 cytokines and TH1-inducing cytokines are not pathogenic and may actually have 
protective roles in autoimmune inflammation. Instead, the novel population of IL-17-secreting 
CD4+ T cells has replaced the TH1 cell subset as the major effector population in 
autoimmunity.  
 The polarization of effector CD4+ T cells relies critically upon the actions of cytokines 
secreted by antigen-presenting cells (APCs). IL-18 is a vital cofactor, together with IL-12, in 
promoting TH1 polarisation and IFNγ secretion. Similar to other TH1 cytokines, IL-12 is no 
longer considered to be a pathogenic molecule in the context of autoimmune inflammation. 
We therefore decided to examine the role of IL-18 and its receptor in the animal model of 
autoimmune CNS-inflammation, Experimental Autoimmune Encephalomyelitis (EAE). As 
with IL-12-deficient mice, we found that IL-18-deficient mice are fully susceptible to EAE. 
Surprisingly, we discovered that mice deficient in IL-18Rα are EAE-resistant, suggesting the 
presence of an alternative ligand with encephalitogenic properties. The actions of this 
alternative ligand could be blocked in vivo using a monoclonal antibody against IL-18Rα, 
which resulted in the abrogation of EAE development. Furthermore, our results establish that 
IL-18 and TH1 development are dispensable for autoimmune inflammation, while IL-18Rα 
engagement on APCs is essential for IL-23 secretion and the subsequent generation of 
encephalitogenic TH17 cells.  
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ZUSAMMENFASSUNG 
 
Organ-spezifische Autoimmunerkrankungen wie Multiple Sklerose oder Rheuma werden von 
autoaggressiven T Helfer (TH) Zellen verursacht. Lange wurde von dem sogenannten TH1/TH2 
Paradigma ausgegangen, dem zufolge TH1 Zellen die pathogene TH-Zellpopulation darstellen, 
wohingegen TH2-Zellen eine förderliche Rolle im Krankheitsverlauf spielen. Ergebnisse aus 
Studien mit genveränderten Mäusen und die kürzlich entdeckten TH17 Zellen stehen im 
Widerspruch zu dieser Hypothese und haben einen Paradigmenwechsel ausgelöst. Man geht 
nun davon aus, dass TH1 Zytokine und TH1 induzierte Zytokine nicht pathogen sind, sondern 
eventuell sogar eine positive Rolle in autoimmunen Entzündungen spielen. Es gelten nicht 
mehr TH1- sondern die unlängst beschriebenen IL-17 sekretierenden CD4+ T Zellen als die 
Haupteffektoren der Autoimmunität. 
Die Polarisierung von Effektor- CD4+ T Zellen beruht vor allem auf der Wirkung von 
Zytokinen, die von Antigen-präsentierenden Zellen (APCs) sekretiert werden. IL-18 ist, 
zusammen mit IL-12, ein entscheidender Cofaktor für die Polarisierung von TH1 Zellen und 
die IFNγ Sekretion. Im Kontext autoimmuner Entzündungen gilt IL-12, wie auch andere TH1 
Zytokine, nicht mehr als pathogenes Molekül. Daher wollten wir die Rolle von IL-18 und 
dessen entsprechendem Rezeptor IL-18R in Experimenteller Autoimmuner Enzephalomyelitis 
(EAE), einem Tiermodell der autoimmunen Entzündung im ZNS, untersuchen. Wir konnten 
beobachten, dass sich der Krankheitsverlauf in IL-18 defizienten Mäusen nicht von dem in wt 
Mäusen unterschied – gleiches wurde bereits für IL-12 defiziente Mäuse gezeigt. 
Überraschenderweise fanden wir, dass IL-18R defiziente Mäuse vollständig resistent gegen 
EAE sind, was auf die Existenz eines alternativen Liganden mit enzephalitogenen 
Eigenschaften für den IL-18R schliessen lässt. Die Wirkung dieses Liganden konnte in vivo 
durch einen monoklonalen Antikörper gegen den IL-18R blockiert werden, wodurch die 
Entwicklung von EAE abgeschwächt werden konnte. Ausserdem zeigen unsere Ergebnisse, 
dass IL-18 und die TH1-Entwicklung für die Entstehung von autoimmunen Entzündungen 
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erlässlich sind, während die Stimulierung des IL-18R auf APCs für die Sekretion von IL-23 
und der folgenden Bildung von enzephalitogenen TH17 Zellen essentiell ist. 
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GENERAL INTRODUCTION 
 
 
AUTOIMMUNE INFLAMMATORY DISEASES 
Autoimmune diseases occur when the complex network of immune cells, that usually act to 
protect the body from pathogenic invasion, initiates an attack against the body’s own tissues 
and organs. The recognition of foreign antigen (Ag) relies critically on the random generation 
of Ag receptors on the surface of lymphocytes. This recombination event yields a high 
number of Ag receptors, some of which are potentially self-reactive. The process of central 
tolerance is designed to recognise and eliminate self-Ag reactive, and therefore possibly 
harmful, lymphocytes. However the healthy immune system does contain circulating self-
reactive lymphocytes that have escaped central tolerance and mechanisms of peripheral 
tolerance exist that operate to control and suppress an outright autoimmune attack by these 
cells (1). Under certain conditions, however, which mostly remain unclear, there is a loss of 
peripheral tolerance to self-Ags that leads to the inappropriate expansion of self-reactive 
effector cells and ensuing tissue inflammation. Autoimmune inflammatory diseases fall into 
two categories: systemic and tissue-specific. Systemic autoimmune diseases, such as systemic 
lupus erythematosus (SLE), affect a variety of organs and mostly result from a humoral 
immune response. On the other hand, tissue-specific autoimmune diseases target one organ 
only. For example, the target tissues of the diseases multiple sclerosis (MS), rheumatoid 
arthritis (RA) and type I diabetes are the central nervous system (CNS), the joint synovium 
and the beta cells of the pancreas, respectively. Furthermore, and in contrast to systemic 
autoimmune inflammation, tissue-specific autoimmune inflammation is generally held to be 
cell-mediated. Auto-reactive T helper cell type 1 (TH1) lymphocytes have long been 
associated with such autoimmune diseases although more recent evidence suggests a role for 
the newly discovered TH17 cells. Despite a central role for TH cells, Ag-presenting cells 
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(APC) are also key players during both the initiation and progression of the autoimmune 
response. APCs perform multifarious tasks in the peripheral immune compartment and, 
importantly, generate guidance cues directing T cell polarization. Consistently, during an 
autoimmune reaction, the development of auto-reactive T cells into pathogenic and 
destructive effector cells relies critically upon the secretion of soluble cytokines by APCs. 
Thus the capacity of APC-derived cytokines to polarise T cells is of significant importance as 
it endows APCs with the potential to either promote or suppress the development of 
autoimmune disease. This thesis presents evidence demonstrating the role for the APC-
derived cytokine IL-18 and its receptor IL-18Rα in the development of auto-reactive TH cells 
and does so in the context of CNS autoimmune inflammation. 
 
CNS AUTOIMMUNE INFLAMMATION 
The CNS has long been considered an organ that is inaccessible to immune cells and hence 
has been referred to as an “immune privileged site”. This hypothesis was based on the 
evidence that grafts and tumours fare much better in the CNS and was mainly attributed to the 
separation of the CNS from the systemic and lymphatic compartments (2-4). The blood-brain 
barrier (BBB) is a highly impermeable capillary endothelium that is formed from specialized 
endothelial cells that are in contact with the endfeet of astrocytes and pericytes (5;6). The 
endothelium is held tightly together by tight junctions, which occludes leukocyte infiltration 
into the CNS, and in contrast to other vasculature, demonstrates little vesicular transport 
activity (7;8). Furthermore, the absence of draining lymphatics from the CNS led to the 
assumption that T cells would never be exposed to CNS Ag (3). Despite the lack of 
communication between the CNS and the periphery, there is mounting evidence that the CNS 
is not as privileged as once thought. Not only can activated lymphocytes readily traffic into 
the CNS through post-capillary venules (9) but CNS Ag is able to drain into the cervical 
lymph nodes (LN) (10), while cells residing within the CNS are themselves capable of 
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presenting Ag (11). Furthermore, extensive inflammatory cell infiltration occurs during CNS 
autoimmune inflammation, which is described below. 
CNS Autoimmune Inflammation in Humans 
MS is an inflammatory and demyelinating disease of the CNS during which immune-
mediated responses are conducted against specific CNS Ag, namely myelin proteins, which 
are present in the protective myelin sheath surrounding neuronal axons. The myelin sheath is 
responsible for the fast conduction of electric impulses along neuronal fibres and its 
destruction results in the characteristic symptoms of MS including sensory and visual 
disturbances, paralysis and lack of coordination (12). The pathological features of the MS 
CNS include distinct foci of inflammatory lesions, containing lymphocytes and monocytes, 
with evidence of demyelination and axonal loss, as well as BBB leakage and astrogliosis (13). 
MS, which follows a recurrent or chronic time-course, develops spontaneously in young 
adults and has a prevalence of 1/1000 in Western Europe. Although the aetiology of the 
disease remains unclear, both genetic and environmental factors have been postulated (14). 
The genetic contribution to MS susceptibility is demonstrated in monozygotic twins, whereby 
there is a 30% concordance in the occurrence of the disease (15). The only major gene locus 
associated with the disease is the human leukocyte antigen (HLA) region, whose products 
encode restriction elements of T cells. An association has been demonstrated between the 
alleles HLA-DR1501 and HLA-DQ0601 and a 2-4 fold increased risk in developing MS in 
white populations (16). The finding of linkage with the HLA allele has strengthened the 
argument that MS pathogenesis does have an autoimmune basis. More conclusive evidence 
though, has been obtained through the use of the animal model for MS, which is known as 
Experimental Autoimmune Encephalomyelitis (EAE). 
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CNS Autoimmune Inflammation in Animals 
The study of MS pathogenesis and the clarification of the events precipitating the disease 
have been aided greatly by the development of the EAE model. EAE can be induced in 
susceptible rodents or monkeys by immunisation with myelin Ag, such as myelin basic 
protein (MBP), myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP) 
(17). Similar to MS, the pathology of this neuroparalytic disorder is characterised by 
lymphocytic and monocytic perivascular infiltration, an increase in BBB permeability, 
astrocytic hypertrophy and demyelination (18;19). In fact, with exception to the mode of 
induction, the steps involved in EAE pathogenesis are thought to parallel those of MS. Similar 
to other organ-specific autoimmune diseases, such as RA and type I diabetes, the pathogenesis 
of CNS autoimmune inflammation is generally held to be cell-mediated, initiated 
predominantly by CD4+ T cells. Furthermore, the immunopathological events can be divided 
into two major phases: an initial T cell priming/activation phase and a subsequent recruitment 
and effector phase (20). T cell priming is initiated in the secondary lymphoid organs where 
professional APCs, such as macrophages and dendritic cells (DC), present Ag to neuroAg-
reactive T cells leading to their activation and expansion. Prior to initiating tissue damage, 
activated myelin-reactive T cells that have migrated to the CNS must first re-encounter their 
cognate Ag. It has been demonstrated that DCs present in the perivascular space of the BBB 
are responsible for presenting Ag to and reactivating activated lymphocytes, which are then 
capable of penetrating deeper into the parenchyma (11). Despite a clear role for the immune 
system in both these events, CNS resident cells play their own role in the effector phase of the 
disease through the generation and maintenance of the inflammatory milieu. Upon damage to 
CNS tissue, the resident macrophages of the CNS, known as microglial cells, upregulate 
major histocompatability complex (MHC) and costimulatory molecules, and secrete cytokines 
and chemokines (21;22). This promotes the continued infiltration of inflammatory cells into 
the CNS, while providing ongoing activation for cells already present in the inflammatory 
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lesion. Certain CNS-derived factors, however, aim to suppress the inflammatory response 
(22). Therefore the CNS micro-environment also has a critical function in the ongoing 
autoimmune attack, which is performed in part by microglia-derived cytokines. 
 
PRINCIPLES OF CELL-MEDIATED IMMUNITY  
Clearly, cell-mediated events of the immune system are critical to the development of MS and 
EAE and autoimmune diseases in general. Therefore I will give a brief overview of the 
workings of the immune system that are relevant to the discussion of the role of APC-derived 
cytokines in EAE pathogenesis. The immune system is divided into two branches, termed the 
innate and acquired immune systems, which fight to protect the host from invading pathogens 
and foreign molecules (23). These branches are not mutually exclusive and in fact they work 
in concert to defend the organism in both a rapid and specific manner. Innate immunity is 
responsible for the first rapid response to Ag and does so at the expense of specificity and 
therefore in a generic fashion.  Acquired or adaptive immunity, on the other hand, is specific 
and can generate immunological memory. A more detailed analysis of the cells and processes 
involved in these separate yet interacting arms of immunity are described in the following 
sections. 
 
Innate Immunity 
Cells of the innate immune system include NK cells, polymorphonuclear macrophages 
(PMNs), monocytes/macrophages and DCs. To defend the host against foreign molecules, 
these cells recognise specific molecular components of invading micro-organisms known as 
pattern-associated molecular patterns (PAMP). Essential features of PAMPs are that they are 
absent in the host and are indispensable components of the invading pathogen allowing 
discrimination between self and non-self and ruling out the possibility of mutation and escape 
by the pathogen (24). PAMPs are recognised by both soluble and membrane-bound mediators 
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of innate immune cells via germ-line encoded receptors called pattern recognition receptors 
(PRR). Soluble mediators include mannose-binding lectins (MBL) (25), C-reactive protein 
(CRP) (26) and complement (27). Membrane bound receptors, which are usually present on 
macrophages and DCs, include the scavenger receptors (28) and most importantly the toll-like 
receptors (TLR) (29). TLRs are the key structures of recognition in the innate immune system 
permitting it to detect a broad range of pathogens including bacteria, viruses, fungi and 
protozoa. To data, 12 TLRs have been identified in mouse and 11 in humans. Stimulation of 
TLRs results in increased phagocytic activity, release of inflammatory mediators and 
production of reactive oxygen species and secretion of cytokines. As will be discussed later, 
the pattern of cytokines secreted during the innate immune response crucially affects the 
development of the subsequent adaptive immune response. 
 
Adaptive Immunity 
The cells of the adaptive immune system are known as B and T lymphocytes and they have 
both high specificity and diversity. These features arise from the ability of the genes encoding 
the B cell receptor (BCR) and T cell receptor (TCR) to undergo genetic recombination. In 
addition, B and T lymphocytes have immunological memory, which allows them to mount a 
faster response, with greater reactivity, upon subsequent recognition. The high 
recombinatorial capacity of these receptors means that, during development, there is 
generation of self-reactive receptors. The mechanism of central tolerance aims to ensure the 
deletion of such self-recognising lymphocytes. Nevertheless, this process isn’t completely 
effective and results in the release of potentially auto-reactive lymphocytes into the 
circulation. As organ-specific autoimmune diseases are predominantly T cell mediated, I will 
briefly describe the processes that prevent the development of self-recognition in the context 
of T cells. 
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 T cells are generated in the bone marrow but must migrate to the thymus for 
maturation. Upon rearrangement of the alpha and beta chains of the TCR, functional receptors 
expressed by thymocytes are selected on the basis of two properties during central tolerance 
(30). The first property is recognition of self-MHC and is known as self-restriction. This is 
important because, as explained later, T cells can only recognise their Ag in the context of an 
MHC molecule. Thymocytes that can recognise self-MHC, expressed by thymic epithelial 
cells, are positively selected for while non-recognition results in apoptosis in a process known 
as positive-selection. The second property is the ability to recognise foreign Ag. In this 
process of negative selection, thymocytes with high affinity for self-MHC or recognising self-
Ag are eliminated by apoptosis ensuring that there is tolerance to self-Ag. During this process, 
thymic epithelial cells, as well as specialised DCs, present self-Ag to the developing T cells. 
This does not pose a problem for ubiquitous Ag but does so for organ-specific Ag, which is 
unlikely to be expressed in the thymus or, when it is, is often sequestered from thymocytes 
(1). Tissue-specific Ag can also be thymically expressed, albeit at somewhat lower levels, as a 
result of transcription factors such as autoimmune regulator (Aire). Indeed CNS-specific Ags, 
such as MBP, and possibly MOG, have been demonstrated to be expressed in the thymus. 
Therefore the presence of mature MBP- and MOG-reactive T cells circulating in the periphery 
is thought to result from specific T cells, with low avidity or recognising particular epitopes, 
being spared negative selection (1). The mere presence of these auto-aggressive T cells in the 
periphery, however, does not dispose or increase susceptibility of individuals to autoimmune 
disease. For example, similar numbers of myelin-reactive CD4+ T cells have been 
demonstrated in the blood and CSF of MS patients and healthy individuals (31). This implies 
that mechanisms of peripheral tolerance provide the “brakes” on the possible development of 
an autoimmune attack.  
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BRIDGING INNATE AND ADAPTIVE IMMUNITY   
Mature T cells are constantly circulating through the blood, lymph and secondary lymphoid 
organs in search of their cognate Ag. However, even in the presence of its Ag, a precise 
sequence of events must occur for the T cell to recognise its Ag and become activated. Unlike 
B cells, T cells cannot directly bind foreign protein or peptide and require help for Ag 
recognition. Instead, APCs of the innate immune system are required for Ag presentation to T 
cells and, as such, these cells function to bridge the innate and adaptive arms of immunity. 
However Ag presentation alone isn’t sufficient for an Ag-specific CD4+ T cell to become 
activated and APCs must deliver three different signals for appropriate T cell activation to 
occur, as described below and illustrated in figure 1.  
 
Signal 1 – Ag Presentation 
The first signal involves the presentation of Ag on the surface of an MHC molecule that 
allows T cell recognition of their cognate Ag though the TCR (Fig. I, left panel) (32). CD8+ 
T cells, which react to extracellular pathogens, recognise their Ag on the surface of a class I 
MHC molecule. CD4+ T cells, on the other hand, react with foreign peptide on the surface of 
class II MHC. With regards to CD4+ T cells and exogenous Ag, APCs must initially 
internalise foreign protein, either by phagocytosis or endocytosis, before proteolytically 
processing it in the endosomal/lysosomal pathway. Ag is thus degraded into small peptides of 
13-18 residues, which can be loaded onto an MHC II molecule and transported to the surface 
for presentation to the TCR/CD3 complex.  
 
Signal 2 – Costimulation 
In order for Ag-specific T cells to become activated and expand, a second signal must be 
generated through the interaction of adhesion and costimulatory molecules on the surface of 
APCs and T cells (Fig. I, middle panel). Indeed, lack of these signals permits maintenance of 
peripheral tolerance to auto-reactive lymphocytes. Adhesion molecules like ICAM-1 and 
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LFA-1 strengthen the immunological synapse by causing closer contact between the 
interacting APC and T cell. Such close interactions are an essential requirement for the 
successful outcome of signal 3, as described below. Costimulatory signals at the immune 
synapse are generated by the B7/CD28 family of cell surface molecules (33). The B7 family 
members are predominantly expressed by APCs. They are either constitutively expressed at 
low levels and subject to upregulation as in the case of B7-2 (CD86) or inducibly expressed as 
with B7-1 (CD80). Both these transmembrane ligands interact with CD28 or CTLA-4, 
another CD28 family member, on the surface of naïve T cells to induce a stimulatory or 
inhibitory signal, respectively. The potent stimulatory signal they provide to T cells, 
previously activated through their TCR, not only leads to productive cell activation but it also 
directs cell expansion and survival as well as growth factor production. Interestingly, CTLA-4 
exhibits a much higher affinity for B7 molecules than CD28 does but, unlike CD28, it is not 
constitutively expressed and undergoes upregulation only upon T cell activation. Thus it 
functions to attenuate the T cell response. Although I have concentrated here on the APC-
derived costimulatory signals necessary for T cell activation, it is important to point out that, 
in a reciprocal manner, T cells simultaneously provide APCs with stimulatory signals. CD40L 
(CD154) expressed by T cells interacts with its receptor CD40, which is present on 
monocytes/macrophages and DCs (34). CD40 signalling has a myriad of effects including cell 
activation and survival, upregulation of costimulatory molecules such as B7-1 and B7-2 and 
CD40 itself, and upregulation of adhesion molecules.  
 
Signal 3 – Cytokine Secretion 
The third signal delivered by APCs (Fig. I, right panel) directs the differentiation of 
activated Ag-specific lymphocytes into an effector T cell subtype. Although both the affinity 
of the peptide-Ag-TCR interaction and costimulatory signals influences the differentiation 
pathway, the secretion of a specific set of cytokines by APCs provides the major signal.  
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These soluble proteins signal in a paracrine fashion via cytokine receptors explaining the 
requirement for adhesion molecule interaction to form close contact between APCs and T 
cells, as described above. The pattern of secreted cytokines depends upon the initial 
stimulation of APCs by PAMPs. TLR triggering stimulates the secretion of a precise set of 
cytokines that ultimately results in a specific reaction against that pathogen by the induction 
of a TH1 or TH2 cell response. Therefore the creation of a particular cytokine environment by 
APCs during immunity is critical for the determination of the appropriate type of immune 
response, which can be either cell-mediated or humoral. Consistently, during an autoimmune 
reaction, the development of auto-reactive T cells into pathogenic and destructive effector 
cells relies critically upon the secretion of soluble cytokines by APCs. It has been 
demonstrated that the APC-derived proteins IL-12 and IL-18 are key players in the 
development of a TH1 cell response and that they synergise with one another by upregulating 
their reciprocal receptors on the surface of TH1 cells (35;36). Alternatively, TH2 cell 
differentiation occurs in the absence of TH1-inducing factors and seems to be promoted solely 
by T cell-derived cytokines, in particular IL-4, subsequent to interaction with APCs (37). The 
precise actions of individual APC-derived cytokines will be described in more detail below 
but first I will discuss the differentiation of CD4+ T cell effector types in more depth. 
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Figure I: T cells require three APC-derived signals for activation. Within the immune 
synapse that forms between APCs and T cells, three signals are required for Ag-specific 
CD4+ T cell activation. Signal 1 comprises the presentation of antigen peptide in the context 
of MHC II molecules, which is recognised by the Ag-specific TCR of the T cell (left panel). 
Signal 2 involves the stabilisation of the synapse through adhesion molecules and the 
generation of signals via costimulatory molecules present on the surface of APCs and T cells 
(middle panel). CD80/CD86 on APCs interacts with their CD28 on T cells to generate 
activatory signals while interaction with CTLA-4 generates inhibitory signals (not pictured). 
Signal 3 is produced by the secretion of cytokines from APCs, which signal via cytokine 
receptors on T cells in order to polarise them towards an effector phenotype (right panel). 
 
 
T CELL DIFFERENTIATION 
 
Concept of the TH1 and TH2 Subset Model 
In 1986, Mosmann et al. initially proposed a model whereby CD4+ T cells are subdivided into 
two independent subsets with distinct effector function (38;39). Their hypothesis suggested 
that TH cells can be segregated into TH1 and TH2 subsets on the basis of cytokine expression 
and bioactivities as well as helper function. Those and further experiments demonstrated that 
TH1 cells predominantly secrete IL-2, IL-3, TNFα and most notably IFNγ and control cell-
mediated functions such as the activation of macrophages, while the secretion of IL-4, IL-5 
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and IL-13 by TH2 cells leads to the stimulation of humoral immunity by aiding B cell 
activation and class switch (39). Interestingly, the cytokines of a particular TH subtype are 
able to further promote the expansion of that subtype whilst simultaneously cross-regulating 
and therefore inhibiting the development of the opposite subset. This allows each TH subset to 
produce characteristic cytokines that in turn provoke the development of a distinctive effector 
function specific for that immunogen. Thus, while TH1 cells induce pro-inflammatory 
responses, such as delayed type hypersensitivity, and eliminate intracellular infections, TH2 
cells function during allergic reactions and anti-helminth responses. More recently, individual 
transcription factors have been identified that are essential for the development of TH1 or TH2 
cells. T-box expressed in T cells (T-bet) is the key transcription factor associated with TH1 
cell development while GATA-binding protein 3 (GATA-3) plays the dominant role in TH2 
differentiation (40;41). Naïve non-differentiated T cells are known as Th0 or TH precursor 
(THp) cells and upon their stimulation by Ag, T-bet and GATA-3 are said to be expressed 
simultaneously at low levels (42). Depending upon the cytokine milieu, either T-bet or 
GATA-3 is upregulated further. T-bet affects TH1 differentiation in several major ways: it acts 
to potentiate IFNγ production, which further promotes T-bet expression in a positive feedback 
loop; it suppresses TH2 cytokine production; it upregulates IL-12Rβ2, the receptor for the 
APC-derived TH1-inducing cytokine IL-12 (43-45). The importance of T-bet in TH1 
differentiation is demonstrated in T-bet-deficient mice, which do not develop TH1 cells and 
are susceptible to TH1 cell-mediated infection (46). Regarding TH2 cells, GATA-3 is 
necessary for the initiation of TH2 differentiation and is indispensable for the production of 
the TH2 cytokines IL-5 and IL-13 (47-49).  
 
Beyond TH1 and TH2 subsets  
In addition to the canonical TH1 and TH2 cell subtypes, additional TH subsets exist that are 
characterised by different effector functions. These include TGFβ-secreting TH3 cells, IL-10-
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secreting Tr1 cells, natural T regulatory (Tregs) cells and IL-17-producing TH17 cells. TH3, 
Tr1 and Treg cells are all regulatory CD4+ T cells that can suppress adaptive T cell responses 
and thus have an important role in controlling autoimmunity (50). While TH3 and Tr1 cells 
develop from CD4+ T cells in the periphery, Tregs represent a diverse lineage that develops 
intrathymically. TH17 cells, on the other hand, are not regulatory and form a new branch of 
CD4+ effector T cell distinct from TH1 and TH2 cells (51;52). Differentiation of naïve CD4+ T 
cells into polarised TH17 cells in vitro occurs through stimulation by APC-derived cytokines 
TGFβ and IL-6, a process that is amplified by IL-1β and is negatively regulated by TH1 and 
TH2 cytokines (53) (Fig. II). Meanwhile, survival and expansion of TH17 cells is thought to 
rely on IL-23 stimulation. Both in vitro and in vivo differentiation of TH17 cells require 
induction of the transcription factor retinoic acid-related orphan receptor-γt (RORγt), which is 
characteristic of this new T cell subset (54). TH17 cells are characterised by the secretion of 
the cytokine IL-17 (also known as IL-17A) but they also produce IL-17F (another IL-17 
family member with closest sequence identity to IL-17A) , IL-6, tumour necrosis factor (TNF) 
(55;56) and IL-22 (57-59). IL-17 is a proinflammatory cytokine that induces the expression of 
IL-1, IL-6 and granulocyte colony stimulating factor (G-CSF), as well as chemokines, by cells 
such as fibroblasts, stromal cells and endothelial cells (60-66). Therefore, in contrast to TH1 
and TH2 cells, which aid the development of a specific immune response and have effects on 
non-immune target cells, the effects of IL-17 so far appear to be limited to non-immune cells.  
 
APC-DERIVED CYTOKINES IN T CELL DIFFERENTIATION 
APC-derived cytokines constitute signal 3 of T cell activation and critically, they determine 
the outcome of T cell differentiation giving them a significant role in governing immunity. 
Until now, no APC-derived factor has been shown to induce TH2 development however IL-12 
and IL-18 are known to be major commanders of TH1 polarisation (Fig. II).  
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Figure II: APC-derived cytokines guide the differentiation of naïve T cells to an 
effector T cell subtype. Secretion of IL-12, in synergy with IL-18, leads to the generation of 
Th1 cells. Initial IL-12 production directs the upregulation of IL-18R and IL-12Rβ2 
expression on the surface of TH1 precursor (TH1p) cells that allows IL-18 to aid IL-12 in 
TH1 polarisation. TGFβ secretion can polarise naïve cells towards a regulatory phenotype or 
an auto-aggressive phenotype depending on the cytokine environment: secretion of TGFβ 
alone by APCs supports regulatory T cell (Treg) formation, from Treg precursor (Treg-p) 
cells, which counteracts autoimmune inflammation. However, the additional presence of IL-
6 results in the production of TH17 cells, which are now considered the pathogenic T cell 
population during autoimmunity. The pathogenic APC-derived cytokine IL-23 is critical for 
the maintenance and survival of these auto-reactive TH17 cells. The interaction of APCs and 
TH2p cells and the absence of IL-12 and IL-18 induce the production of the TH2 cytokine IL-
4 from T cells, which acts in an autocrine fashion to polarise committed TH2 cells. 
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IL-12 – the Major TH1-Inducing Cytokine 
IL-12 is a heterodimeric cytokine of 70 kDa consisting of heavy (p40) and light (p35) 
subunits, which are covalently linked (67-69). IL-12 is produced mainly by APCs, in 
particular by DCs and macrophages, although it can also be secreted by PMNs. While p40 
appears to be produced in abundance in these cell types, the production of p35 is ubiquitously 
and constitutively expressed only at low levels and it requires p40 coexpression for secretion 
of the biologically active cytokine from the cell (70). IL-12 is mostly secreted upon TLR 
activation and it therefore acts as an early proinflammatory cytokine in response to many 
infectious agents (24). IL-12 signalling has a multitude of effects during an immune response: 
It acts upon NK cells and CD8+ T cells to increase their cytotoxic activities; it stimulates the 
production of cytokines, in particular and most importantly IFNγ but also GM-CSF, TNF and 
IL-2 that are necessary for the ensuing immune response; it drives further production of IL-12 
from DCs and macrophages in a positive feedback loop and finally it drives the differentiation 
of naïve T cells to an IFNγ-producing TH1 effector cell phenotype (71). Thus, IFNγ is an 
important mediator of the effects of IL-12. IL-12 is the most critical cytokine promoting TH1 
differentiation and expansion although its actions can be influenced by the presence of other 
cytokines. IL-18, for example, synergises with IL-12 in TH1 differentiation (Fig. II) while 
TH2 cytokines such as IL-4, IL-5 and IL-13 reciprocally oppose IL-12 and TH1 development 
(71).  
 IL-12 signals through the heterodimeric IL-12 receptor (IL-12R) which is formed by 
IL-12Rβ1 and IL-12Rβ2 subunits and which predominantly bind to p40 and p35 chains, 
respectively (72). Coexpression of both subunits is required for the generation of high affinity 
binding sites for p70 binding and IL-12Rβ2 is the critical signal transducing subunit of the 
receptor complex (73). The IL-12R is predominantly found on NK cells and activated T cells 
but it has also been demonstrated on the surface of APCs implying an autocrine effect 
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(74;75). The expression of IL-12Rβ2 on TH1 cells is tightly regulated with its expression 
being maintained by IFN-γ and T-bet expression and inhibited by the TH2 cytokine IL-4.  
IL-18 – a Pleiotropic Cytokine 
IL-18 is an 18 kDa proinflammatory cytokine and a member of the IL-1 superfamily of 
cytokines although its activities are more similarly related to those of IL-12. In fact, this 
cytokine was initially described as the IFNγ-inducing factor (IGIF) (76). IL-18 is expressed 
by macrophages and DCs in response to TLR activation but is also produced by epithelial 
cells, keratinocytes and other stromal cells (77). It is produced as a 24 kDa inactive precursor 
protein (pro-IL-18) lacking a signal peptide and, like IL-1β, must be cleaved by caspase-1 
(also called IL-1β-converting enzyme (ICE)) to its biologically active form (76;78;79). IL-18 
signals through the IL-18R, a heterodimeric complex of an IL-18Rα-binding subunit and an 
IL-18Rβ signalling subunit (also termed IL-1RAcPL or IL-1R7) (80-82). The extracellular 
portion of IL-18Rα is responsible for IL-18 binding. However this requires the presence of 
the receptor β-subunit, which composes the high affinity receptor complex. IL-18R is 
expressed by a variety of immune cells including lymphocytes, NK cells, macrophages and 
neutrophils (83-85). As a result, IL-18 has pleiotropic effects although it is best known for 
stimulating the cytotoxic activities of NK cells and promoting TH1 differentiation and IFNγ 
production through its synergistic activities with IL-12 (Fig. II). The synergism of IL-12 and 
IL-18 in TH1 polarisation results from the reciprocal enhancement of their signalling 
pathways (86-88) as well as the upregulated expression of each other’s receptors on Th1 cells 
(35;36;89). Interestingly, despite its prominent feature as a TH1 inducer, IL-18 can also 
promote TH2 cytokine production in the absence of IL-12 and in an IL-4-dependent manner 
(77). 
 IL-18R activation initiates a downstream signalling pathway that is shared with other 
IL-1 and TLR family members (90). This includes recruitment of MyD88 to the receptor 
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complex and phosphorylation and activation of IL-1R-associated kinase (IRAK) and the 
adaptor molecule tumor necrosis factor receptor-associated factor 6 (TRAF6). Intracellular 
signalling ultimately leads to the phosphorylation and degradation of the inhibitory IκB 
kinases thereby liberating the transcription factor NFκB and permitting its translocation to the 
nucleus for gene transcription. In addition, IL-18R signalling has been demonstrated to 
activate members of the MAPK family. 
 
THE ROLE OF CELL-MEDIATED IMMUNITY IN AUTOIMMUNE 
INFLAMMATION 
TH1/TH2 Paradigm of Autoimmunity 
Until recently, the development of autoimmune diseases was also governed conceptually by 
the TH1/TH2 subset model, whereby it was widely held that TH1 cells form the pathogenic T 
cell subset in the context of tissue specific T cell driven autoimmune diseases, while TH2 cells 
are thought to mediate allergic responses and asthma. Conversely TH2 cells were reported to 
exert beneficial function during tissue-directed autoimmune disease pathogenesis (91). With 
regards to autoimmune inflammation of the CNS, this paradigm was proposed on the basis of 
several observations: tissue-invading TH cells normally express IFNγ (92); Th1-inducing 
cytokines are present in the inflammatory lesion and often correlate with disease severity (93); 
EAE can be induced by the adoptive transfer of encephalitogenic TH1 cells (94;95). Indeed 
treatment of mice with TH1-inducing cytokines mostly results in aggravation of autoimmune 
diseases, such as EAE (for a list of reports in support of the TH1/TH2 paradigm of 
autoimmunity see Table I). 
However, in stark contrast to this data, the generation and immunisation of mice 
deficient in TH1 cytokines such as IFNγ and TNFα demonstrated that they were not, in 
contrast to expectations, protected from autoimmune disease. Disease progression and 
severity of both EAE in TNFα-deficient mice was identical to that in wt mice, while IFNγ- 
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and IFNγR-, deficient mice were hypersusceptible to disease (96;97). Loss of IFNγ even 
causes disease resistant mouse strains to develop EAE (98). In addition, deletion of TH2 
cytokines generally did not affect the progression of autoimmune disease (99). The disease-
exacerbating effects of TH1 cytokine deficiency thus presents a dichotomy as it suggests 
protective effects for TH1 cytokines. Despite these contradictory results, autoimmunity has 
persisted to be defined by the TH1/TH2 paradigm mostly due to data describing autoimmune 
disease in mice deficient either in the transcription factor for IFNγ or in TH1-inducing 
cytokines. Consistent with a role for TH1 cells  and IFNγ in autoimmunity, mice deficient in 
the TH1 transcription factor T-bet are resistant to the induction of several experimental 
autoimmune diseases, such as EAE, inflammatory bowel disease (IBS) and SLE (100-103). 
Protection from disease correlated with a skewing in the ratio of the TH1/TH2 response 
towards a more dominant TH2 environment that included significant upregulation of the TH2 
cytokines IL-4, IL-5 and IL-10. Conversely, inhibition of the TH2 transcription factor GATA-
3 reduces TH2 cytokine expression thereby decreasing allergic airway inflammation and 
hyper-responsiveness (104).  Such an imbalance in the TH1/TH2-inducing transcription factors 
has also been observed during human disease whereby relapsing-remitting MS patients have 
an increased expression of T-bet in peripheral blood leukocytes during relapse (105). On the 
other hand, increased gene expression of GATA-3 and reduced expression of T-bet have been 
demonstrated in the airways of patients with asthma (106;107). In light of the above data 
(Table I), immune modifying strategies for the treatment of autoimmune inflammation have 
focused on the concept of immune deviation (for review see Nicholson & Kuchroo) (108), 
whereby auto-aggressive TH1 cells are deviated towards a TH2 polarized phenotype. Taken 
together, while the TH1/2 paradigm of autoimmunity has been bombarded with conflicting 
data, the fact that T-bet-deficient mice, as well as mice deficient in APC-derived TH1 
inducing cytokines, are resistant to the induction of Ag-driven autoimmune diseases has held 
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this paradigm firmly in place. I will now discuss the role of APC-derived cytokines and the 
paradigm shift that was finally initiated by a number of key findings. 
 
Evidence for a Pathogenic Role of IL-12 in Autoimmunity 
APC-derived cytokines constitute signal 3 of T cell activation and, critically, they determine 
the outcome of T cell differentiation giving them a significant role in governing 
autoimmunity. Mice deficient in the TH1-inducing cytokines IL-12 and IL-18 have been 
shown to be resistant to EAE, again coinciding with reduced TH1 development. In addition, 
the treatment of mice with neutralizing antibodies against IL-12p40 effectively prevents 
disease induction and suppresses EAE in adoptive transfer recipients (109). The treatment of 
mice with recombinant IL-12 is capable of exacerbating EAE and is again thought to result 
from enhanced activation of IFNγ-producing T cells (110). Of significant importance, roles 
for Th1-inducing cytokines can also be derived from the human disease. In MS, patients 
demonstrate increased levels of  IL-12 in serum (111), cerebrospinal fluid (CSF) (112), MS 
lesions and peripheral blood mononuclear cells (PBMC) when compared to controls (113). It 
has also been shown that augmented IL-12 expression is representative of the degree of 
disability whereby IL-12p40 mRNA is elevated in MS patients during the development of 
active lesions and immediately prior to relapses during relapsing-remitting MS (114). 
Therefore, data from human autoimmune disease as well as the animal model both point 
towards a highly relevant role for TH1 inducing conditions and IFNγ production in 
autoimmune pathogenesis (Table I). 
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Table I: Evidence for TH1 Pathogenesis in Autoimmunity References 
 
TH1 cytokines in multiple sclerosis 
• ↑ IL-12 demonstrated in plasma, CSF, PBMCs and MS plaques of MS patients 
• Higher percentage of IL-12Rβ1 and IL-12Rβ2-expressing T cells in CSF of MS 
patients compared to blood 
• ↑ IL-18 expression in serum, PBMCs and demyelinating lesions of MS patients 
• ↑ serum levels of IFNγ in RR-MS patients prior to onset of relapse 
• Significant positive correlation between IFNγ-producing PBMCs and MS 
disability 
• ↑ IL-12, IL-2, IFNγ, TNFα, IL-1β and IL-6 in PBMCs of acute and relapsing 
MS patients 
 
TH1 cytokines in experimental autoimmune encephalomyelitis 
• Anti-IL-12p40 Ab suppresses EAE in adoptive transfer recipients 
• IL-12p40-deficient mice are resistant to MBP-induced EAE  
• Anti-IL-18 Abs significantly ↓ IFNγ production and disease development 
during MBP-induced EAE in rats 
• IL-18-deficient mice are resistant to MOG35-55-induced EAE due to decreased 
IFNγ 
• CNS-infiltrating cells of EAE mice stained for IFNγ and IL-2 
• CD4+ T cells infiltrating the CNS of acute EAE mice produced the Th1 
cytokines IL-2 and IFN-gamma 
• T-bet-deficient mice completely fail to generate Th1 cells and thus are resistant 
to MOG35-55-induced EAE 
 
 
 
(111-117) 
(118) 
 
(119-121) 
(122) 
(123) 
 
(117) 
 
 
 
(124) 
(125) 
(126) 
 
(84) 
 
(93) 
(92) 
 
(100) 
 
Evidence against a Pathogenic Function for IL-12 in Autoimmunity 
As explained above, IL-12 is a heterodimeric cytokine consisting of p35 and p40 subunits. 
The wealth of data pertaining to IL-12’s role in autoimmunity originated from using mice 
deficient in the p40 subunit of IL-12 as well as administering antibodies which turned out to 
be specific against IL-12p40, both of which abolish expression and/or the function of IL-12. 
However, a series of reports have led to a revised concept of IL-12 function in autoimmune 
disease, starting in 1999 with further evidence that the p40 subunit is able to dimerise with 
 28
subunits other than p35. While it was previously known that p40 could homodimerise to form 
p80 with putative IL-12 antagonistic activities, Oppmann and colleagues identified an IL-
6/IL-12-related subunit, p19, with which p40 heterodimerises to form the cytokine IL-23 
(127). Upon ubiquitous transgenic expression of p19 in mice, Wiekowski et al. could show 
that p19 has similar biological properties to IL-6, G-CSF and IL-12, which resulted in the 
induction of multi-organ inflammation in these animals (128). In 2002, Becher et al 
demonstrated that immunisation of mice deficient in IL-12p35 were surprisingly not resistant 
to MOG-induced EAE but actually had increased clinical severity, a finding that could also be 
reproduced by others (129;130). Interestingly, the conflicting phenotypes were accompanied 
by a decrease in TH1 immunity in both genotypes. In addition, mice lacking the p40-binding 
subunit of IL-12, IL-12Rβ1, were also EAE resistant, but the p35-binding subunit, IL-12Rβ2, 
was shown to be irrelevant (131). The discordant effects of IL-12p40 and IL-12p35 clearly 
suggest an indispensable role for p40 in experimental disease but not for IL-12. The 
incompatibility of the p40 and p35 phenotypes seemed likely to result from the promiscuity of 
the p40 subunit, whereby resistance of p40-deficient mice resulted from the lack of IL-23 and 
not IL-12. This was later confirmed in mice deficient in the IL-23 subunit p19, and therefore 
in IL-23 alone, which in resemblance to p40-deficient mice, were protected from both EAE 
and CIA (132;133) (Table II). In contrast to p40-deficient mice, p19 deficiency does not 
impact on the development of TH1 cells and IFNγ production, which provides further and 
overwhelming evidence against a critical pathogenic role for TH1 in autoimmunity. 
IL-23 is secreted by APCs and signals via the IL-23R that is made up of the p40-
binding IL-12Rβ1 subunit and the signalling IL-23R subunit, which together form the high 
affinity receptor complex for IL-23 (134). IL-23R is present on the surface of various cells of 
the immune system including activated/memory T cells, NK cells, DCs, monocytes and 
macrophages (135). In contrast to IL-12R, IL-23R is highly expressed on murine memory 
CD4+ T cells, and is expressed at low levels on naïve T cells, permitting unique effects for IL-
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23 on this cell type. As demonstrated in p19-/- mice, IL-23 does not affect TH1 polarization as 
observed by an intact IFNγ response (56). Alternatively, IL-23 is one of the factors essential 
for the expansion and survival of the newly-defined TH17 cell. 
 
TH17 cells in Autoimmune Inflammation 
TH17 cells and the expression of IL-17 have been associated with numerous human 
autoimmune diseases including RA (136;137) and MS (138;139). Furthermore, its inhibition 
or deletion in the corresponding animal models has provided a varying degree of protection 
(56;140-143). In light of this emerging T cell subset, some of the previously observed 
discrepancies in the TH1/TH2 paradigm of autoimmunity could be explained, especially with 
regards to the conflicting data obtained for IL-12p40- and IL-12p35-deficient mice. Cells 
from EAE resistant IL-12p40-/- mice demonstrate both defective TH1 and TH17 responses 
while cells from hyper-susceptible IL-12p35-/- mice, which still express IL-23, lack TH1 
development but have an elevated frequency of TH17 cells (51;144). Consistently, EAE-
resistant IL-23p19-/- mice show normal TH1 responses but have a significantly reduced 
production of IL-17. Adoptive transfer experiments showed that encephalitogenic CD4+ T 
cells that had been treated in vitro with Ag and IL-23, but not IL-12, could induce EAE in 
recipient mice (56). In accordance with a role for IL-23 in the expansion and survival of TH17 
cells, IL-23 has been demonstrated to be required during the effector phase of EAE (132;145). 
The generation of bone marrow chimeric mice, in which p40 was expressed either in the CNS 
or the peripheral immune system, showed that p40 is not absolutely required for the 
infiltration of inflammatory cells into the CNS but that p40 produced by cells resident to the 
CNS is essential for maintaining encephalitogenicity of T cell migration into the CNS (145). 
Furthermore, Cua et al showed that injection of IL-23 into the CNS of p19-/- mice abrogated 
resistance of these animals to EAE (132). They suggest that the role of IL-23 in promoting 
encepalitogenicity results from its activation of macrophages, present in the inflamed CNS, to 
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produce proinflammatory cytokines such as IL-1 and TNF. This points to an important role 
for IL-23 in the regulation of myeloid cells in organ-specific autoimmune diseases. Therefore 
IL-23 and not IL-12 is required for mediating the pathogenesis of CNS autoimmune 
inflammation, which is subsequently, to some extent, modulated by the IL-12-IFNγ pathway 
(for a list of reports rejecting the TH1/TH2 paradigm see Table II). 
 
Table II: Evidence against TH1 Pathogenesis in Autoimmunity References 
 
• IL-12p35-/- mice are susceptible to EAE 
• IL-23-/- mice are resistant to EAE 
 
• IFNγ-/- mice are hypersusceptible to EAE 
• IFNγ-/- and IFNγ receptor deficient mice are not protected from CIA 
• TNFα-/- mice are not resistant to EAE 
• IL-4-/- mice are not hypersusceptible to EAE 
 
• IL-23 induces a population of encephalitogenic CD4+ T cells called TH17 
cells 
• IL-17 block or deficiency  reduces susceptibility to EAE and CIA 
 
• IL-17 mRNA is augmented in blood and CSF mononuclear cells of MS 
patients 
• IL-17 is produced by the rheumatoid synovium  
 
 
(129;130;146) 
(132) 
 
(96;98) 
(147-149) 
(97) 
(99) 
 
(56) 
 
(56;140;141;143) 
 
(138) 
 
(136) 
 
 
IL-18 in Autoimmune Inflammation 
The above evidence clearly argues against a role for IFNγ-secreting TH1 cells in the 
pathogenesis of autoimmune disease and suggests a more regulatory role for this subset. 
However the known actions of IL-18, as well as the previously discussed role of T-bet, have 
prevented completely dismissing this paradigm. Mice deficient in the TH1-inducing cytokine 
IL-18 have been shown to be protected from MOG35-55-induced EAE and are deficient in 
mounting auto-reactive TH1 responses (84). The defective TH1 cell response was suggested to 
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result at least in part from abrogated IFNγ production by NK cells, as transfer of NK cells 
from recombination activating gene (RAG)-deficient, but not from IFNγ-/-, mice were able to 
rescue the susceptibility of these mice to EAE. In addition, the administration of anti-IL-18 
antibodies (Ab) to MBP-immunised rats significantly reduced the production of IFNγ as well 
as disease development. With regards to human autoimmune disease, increased IL-18 
expression has been demonstrated in the serum (119), PBMCs (121) and actively 
demyelinating lesions (120) of MS patients.  These data point towards a role for IL-18 in CNS 
autoimmune inflammation at the level of T cell priming and TH1 induction (Table I), which is 
surprising given the clearly protective effects of IL-12 and other TH1 cytokines. This could 
suggest, however, that IL-18 is capable of compensating for the lack of IL-12 in IL-12p35-/- 
mice thereby implying redundancy in auto-reactive TH1 cell development.  
The role of IL-18 in CNS autoimmune inflammation has mainly focused on its 
influence upon TH1 polarization and NK cell activation. With regards to the effector stage of 
disease, there is a lack of data pertaining to the role of IL-18 in MS and EAE pathology. IL-18 
has been detected in the mouse brain in vivo and microglia were postulated to be the potential 
producers as cultured microglia was capable of producing IL-18 upon stimulation with LPS 
(150). Indeed, IL-18 mRNA expression has been shown to increase in the CNS during acute 
EAE and IL-18 induces the expression and release of cytokines from murine glial cells (151). 
In addition, IL-18 and IL-12 have been shown to induce IFNγ production and MHC II mRNA 
expression in microglia (152). Although Shi et al have demonstrated that IL-18-/- mice are 
susceptible to the adoptive transfer of encephalitogenic wt lymphocytes implying that IL-18 
has no role in the CNS, it has been suggested that IL-18 may act to terminate the immune 
response in the CNS due to its role in Fas/Fas ligand mediated apoptosis (151). Taken 
together, the role of the TH1-inducing cytokine IL-18 remains improperly characterised with 
regards to its actions in the CNS during the effector phase of EAE and in the context of the 
changing TH1/TH2 paradigm of autoimmunity. 
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SPECIFIC AIMS  
 
The aims of this PhD thesis were: 
 
1. The assessment of the role of IL-18 as a compensatory factor in IL-12-deficient mice 
during CNS autoimmune inflammation 
 
2. Characterisation of the role of IL-18 in the effector stage of CNS autoimmune 
inflammation 
 
3. Characterisation of the role of IL-18Rα in CNS autoimmune inflammation 
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 MATERIALS AND METHODS 
 
MICE 
Female C57BL/6 mice were purchased from Harlan Laboratories (Netherlands). IL-12p35-/-, 
IL-12p40-/- and OT-II (C57BL/6-Tg(TCRaTCRb)425Cbn/J) mice were purchased from 
Jackson Laboratories (USA). Homozygous IL-18-/- and IL-18Rα-/- (all backcrossed onto 
C57BL/6 for more than 12 generations) were provided by S. Akira (Osaka) and Rag1-/- mice 
were provided by R. Zinkernagel (Zurich) and were bred in house under specific pathogen 
free (spf) conditions. The 2d2 (MOG-TCR-Tg) mice were provided by V. Kuchroo (Harvard 
Medical School, Boston, Massachusetts). Animal experiments and breeding were approved by 
the Swiss Veterinary Office (#69/2003 and #70/2003). 
Bone Marrow Chimera Generation 
Irradiation Bone Marrow (BM)-chimeric mice were generated as previously described (11). 
Briefly, BM-donor mice were euthanized using CO2 and BM-cells were isolated by flushing 
femur, tibia, radius and hip bones with phosphate buffered solution (PBS). BM cells were 
then passed through a 100 μm cell strainer and cells were washed with PBS. Recipient mice 
were lethally irradiated with 1100 rads (split dose) and i.v. injected with 12-25x106 BM-cells. 
Engraftment took place over 8 weeks of recovery.  
 
EAE INDUCTION AND EVALUATION 
 
Active Immunisation 
Mice were immunised subcutaneously with 200 μg of MOG35-55 (amino acid sequence: 
MEVGWYRSPFSRVVHLYRNGK), obtained from GenScript (Piscataway, NJ), emulsified 
in CFA (DIFCO, Detroit, MI). Mice received 200 ng pertussis toxin (PtX) (Sigma-Aldrich) 
intraperitoneally at the time of immunization and 48 hours later. Monoclonal anti-IL-18Rα 
antibody (clone 112624) (R&D Systems) was administered either 1 day pre-immunisation 
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(450 μg/mouse) and every 3 days thereafter (300 μg/mouse) or every 3 days beginning from 
disease onset (300 μg/mouse). Clinical disease usually commences between days 10 and 14 
post-immunisation and between days 6 and 10 for BM-chimeric mice. 
 
Passive Immunisation 
For adoptive transfer, MOG-reactive T cells were generated as described (153). Briefly, donor 
mice were immunised with 200 μg of MOG35-55 peptide in CFA and given 200 ng PtX at the 
time of immunisation only. After 11 days, LNs and spleens were isolated, homogenised and 
the single cell suspensions were filtered through a 100 μm cell strainer before centrifugation 
at 1500 r.p.m. for 10 min at 4°C. For lysis of red blood cells (RBCs), splenocytes were 
incubated on ice for 10 mins in lysing buffer (containing NH4Cl, KHCO3 and EDTA). The 
cells were then washed with PBS, centrifuged and filtered a second time before counting. LN 
cells and splenocytes were resuspended and plated at a concentration of 4x106 cells/ml in 
RPMI medium containing 10% FCS, 1% penicillin/streptomycin, 1% glutamine and 50 μM β-
mercaptoethanol (RPMI complete) with the addition of 50 μg/ml MOG35-55 and 2.5 ng/ml of 
recombinant IL-12 (Peprotech). Cells were left in culture for 4 days at which point they were 
scraped from the culture plate, washed and counted. Mice were injected i.p. with 25x106 cells 
and received 200 ng PtX several hours later and on day 2 post-injection. Clinical disease 
usually begins 6-10 days after cell transfer. 
 
Clinical Evaluation 
Mice were scored daily as follows: 0) no detectable signs of EAE; 0.5) distal tail limp; 1) 
complete tail limp; 2) unilateral partial hind limb paralysis; 2.5) bilateral partial limb 
paralysis; 3) complete bilateral hind limb paralysis; 3.5) complete hind limb paralysis and 
unilateral forelimb paralysis; 4) total paralysis of fore and hind limbs (score > 4 to be 
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euthanized); 5) death. Each time point shown is the average disease score of each group. 
Statistical significance was assessed using an unpaired Student’s t-Test (∗ < 0.05; # < 0.01). 
 
Histology  
Mice were euthanised with CO2, followed by transcardial perfusion with PBS and subsequent 
perfusion with 4% (weight/volume) paraformaldehyde (PFA) in PBS. The spinal column was 
removed and fixed in 4% PFA in PBS. The spinal cord was then dissected and paraffin-
embedded prior to staining with either haematoxylin & eosin (H&E) or CD3, B220 and 
MAC-3 antibodies (BD Pharmingen) to assess infiltration of inflammatory cells. Luxol fast 
blue (LFB) stain was used to determine the degree of demyelination or amyloid precursor 
protein (APP) was used to assess the extent of axonal damage.  
 
CELL ANALYSIS 
Flow Cytometry 
For cytofluorometric analysis we used the following antibodies diluted in facs buffer (PBS 
supplemented with FCS and sodium azide): anti-CD45 (30/F11), anti-CD4 (RM4-5), anti-
Vα3.2 (RR3-16), anti-CD11b (M1/70), anti-GR-1 (RB6-8C5) and anti-B220 (RA3-6B2), 
anti-CD80 (16-101), anti-CD86 (GL1), anti-CD40 (3/23), anti-CD62L (Mel-14), anti-CD162 
(2Ph1), anti-VLA-4 (R1-2), anti-CD5 (53-7.3), anti-CD25 (PC61), anti-Ly5.1 (104), anti-
Ly5.2 (A20), anti-IL-18Rα (clone 112624), anti-IL-17 (TC11-18H10) and anti-IFN-γ 
(XMG1.2). All antibodies were purchased from BD Pharmingen except from anti-IL-18Rα 
(clone 112624), which was bought from R&D Systems.  
For analysis of CNS invading cells, mice were euthanised with CO2 and perfused 
intracardially with PBS. Spinal cord was flushed out with PBS and the brain was dissected to 
isolate the brainstem. Tissues were digested using liberase treatment (400 μg/ml liberase 
(Roche) and 200 μg/ml DNase (Roche)) at 37°C for 30 min. The tissues were then 
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homogenised and strained through a 100μm nylon filter (Fisher). After centrifugation, cell 
suspensions were resuspended in 30% Percoll (Pharmacia) and centrifuged at 18,500g for 30 
min at 4°C. Interphase cells were collected and washed extensively before being staining. For 
flow cytometry, we incubated the primary antibody for 20 min at 4°C. Cells were then 
washed with facs buffer and centrifuged for 2 min at room temperature (RT) prior to staining 
for 15 min with the secondary antibody at 4°C. Cells were washed, centrifuged and 
resuspended in 300 μl facs buffer for subsequent analysis. We analysed the cells using a 
FACSCalibur (BD Pharmingen) with CellQuest software. Post-acquisition analysis was 
performed using WinMDI 2.8 software (Scripps-Research Institute). 
 
Recall Assays 
Spleen, axillary and inguinal lymph nodes were isolated from naïve mice or mice primed by 
injections of 100 μg/flank of MOG35-55 or KLH (Sigma) emulsified in CFA 7 days earlier. 
2x105 cells were placed as triplicates in 96-well plates and stimulated for 48 hours with either 
50 μg/ml KLH, 5 μg/ml ConA or medium. After 24 hours, 0.5 μCi/ml 3[H]-thymidine was 
added to the wells and incubated for an additional 24 hours to observe proliferative responses. 
Thymidine incorporation was assessed using a Filtermate Harvester and a scintillation and 
luminescence counter. Briefly, samples were harvested onto glass fibre filter paper (Wallac) 
using a Filtermate Harvester. The filter paper was microwaved for 4 min to dry and placed in 
a plastic sample bag (Perkin Elmer), which was subsequently filled with 4.5 ml scintillation 
fluid. Scintillation fluid was spread over the filter and the remainder was expelled from the 
bag. The bag was then sealed and placed in the luminescence counter for detection of beta 
counts. For cytokine analysis, the culture supernatant of identical sister cultures was harvested 
after 48 hours and analysed in duplicate for IFN-γ, IL-17 and IL-23p40 production by ELISA 
(Pharmingen, La Jolla, CA). 
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ELISpot 
For ELISpot assays, lymphocytes were isolated from the CNS of MOG35-55-immunised mice 
on days 9 and 14 dpi by differential Percoll centrifugation as described above. Cells (2 x 105) 
were plated in complete RPMI containing 50 μg/ml MOG35-55 in 96-well plates (Millipore) 
coated with 7.5 μg/ml anti-IFN-γ (AN18; Mabtech) or 2 μg/ml anti-IL-17 (TC11-18H10; BD 
Pharmingen) Abs. The plates were incubated at 37°C, 5% CO2 for 18 (anti-IL-17) or 20 (anti-
IFN-γ) hours at which point cells were discarded and plates were washed with PBS. Then, 0.5 
μg/ml of biotin-conjugated anti-IFN-γ (R4-6A2; Mabtech) or 1 μg/ml of biotin-conjugated 
anti-IL-17 (TC11-8H4.1; BD Pharmingen) detection Abs was added and incubated at 25°C 
for 2h and 4 h, respectively. After plates were washed, streptavidin-alkaline phosphatase 
(Mabtech) was added, followed by incubation for 1 h at 25°C. Plates were washed with PBS 
and 75 μl of the substrate solution BCIP/NBT-plus (5-bromo-4-chloro-3-indolylphosphate-
nitro blue tetrazolium) was added to the wells, which were developed until distinct spots 
emerged. Plates were analysed with an enzyme-linked immunospot reader (Immunospot; 
CTL). 
 
CYTOKINE ANALYSIS 
Naïve Cells 
To detect cytokine secretion from naïve cells, LNs were isolated from naïve wt, IL-18-/- and 
IL-18Rα-/- mice, homogenised and 2x105 cells were plated in triplicate in a 96-well plate. 
5μg/ml ConA was used for stimulation for 16 hours and 5μg/ml anti-CD40 (FGK) was used 
for stimulation for 36 hours before analysing IFNγ or IL-23p40 production by ELISA (BD 
Pharmingen), respectively. CD4+ T cells were purified from naïve splenocytes using BD 
IMag Magnetic Beads (BD Pharmingen) and stimulated with 5 μg/ml anti-CD3 (2c11) and 5 
μg/ml anti-CD28 (37N) for 36 hours before analysing IFN-γ production by ELISA.  
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CNS Tissue 
To detect cytokine expression in the CNS, naïve mice or mice with EAE were sacrificed with 
CO2 and transcardially perfused with PBS. The spinal cord was flushed out and the brain was 
dissected to isolate the brainstem. The CNS was homogenised on ice for 15 min in a 
homogenisation buffer containing 20 mM Tris/HCl (pH 7.3), 140 mM NaCl, 0.5% Triton X-
100, 2 mM activated sodium orthovanadate and 1 tablet/50 ml Complete protease inhibitor 
(Boehringer Ingelheim). After homogenisation, the suspension was sonicated 3 times for 10 
sec on ice, ensuring that the sample didn’t become too hot. The extracts were then cleared 
from myelin by centrifugation at 2000 rpm for 10 min at 4°C. The supernatant containing 
cytokines was then added directly to the ELISA plate to detect expression of IL-18 in the 
CNS (BD Pharmingen). 
 
REAL-TIME PCR  
RNA Isolation and cDNA Synthesis 
Spleen, axillary and inguinal lymph nodes were isolated from naïve mice or mice primed by 
injections of 100 μg/flank of MOG35-55 or KLH emulsified in CFA 7 days earlier. 4x106 cells 
were plate in 6 well plates and stimulated with 50μg/ml of the cognate Ag or medium. After 2 
days, RNA was isolated from restimulated cells by TRIzol extraction (Invitrogen). For RNA 
isolation, 200 μl isopropanol was added per ml of TRIzol and then samples were shaken 
vigorously, incubated for 3 min at RT and then centrifuged at 8000 rpm for 15 min at 4°C. 
The colourless upper phase was collected, added to a new, sterile eppendorf tube and RNA 
was precipitated by mixing with 500 μl chloroform. After 10 min incubation at RT, the 
samples were centrifuged again at 8000 rpm for 10 min at 4°C. The supernatant was discarded 
and the pellet was washed once with 75% ethanol. Samples were centrifuged at 5000 rpm for 
10 min at 4°C, the ethanol was discarded and the pellets were left to dry at RT prior to 
resuspension in RNase-free water. For cDNA synthesis, 1-5 μg RNA was reverse transcribed 
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using Moloney Murine Leukemia Virus reverse transcriptase (M-MLV RT) (Invitrogen), 
which uses single stranded RNA to synthesise a complementary cDNA strand in the presence 
of a primer. The following components (all from Invitrogen) are mixed gently together in a 
tube and heated at 37°C for 5 min prior to adding M-MLV RT: 5X First strand buffer, dNTPs, 
DTT, random primers and Recombinant Ribonuclease Inhibitor RNaseOUT. The mix is then 
added to the RNA and incubated at RT for 10 min, 37°C for 50 min and 70°C for 15 min to 
inactivate the reaction. 
 
Real-time PCR Analysis 
Diluted cDNA was mixed with the following components. Real-time PCR was carried out to 
analyse RNA expression of cytokines and chemokines using the following primer sequences: 
• IL-17 forward: ATCAGGACGCGCAAACATGA 
• IL-17 reverse:  TTGGACACGCTGAGCTTTGA 
 
• IFNγ forward: GCATTCATGAGTATTGCCAAG 
• IFNγ reverse:  GGTGGACCACTCGGATGA 
 
• IL-23p19 forward: CTG TTG CCC TGG GTC ACT CA 
• IL-23p19 reverse: CAC ACT GGA TAC GGG GCA CAT TA 
 
• IL-23p40 forward: TTTGCTGGTGTCTCCACTCA 
• IL-23p40 reverse:  CATCTTCTTCAGGCGTGTCA 
 
• IL-1 forward: CAACCAACAAGTGATATTCTCCATG 
• IL-1 reverse:   GATCCACACTCTCCAGCTGCA  
 
• TNFα forward: CATCTTCTCAAAATTCGAGTGACAA 
• TNFα reverse:  TGGGAGTAGACAAGGTACAACCC 
 
• Rantes forward: TGCCCACGTCAAGGAGTATTT                   
• Rantes reverse:  TCTCTGGGTTGGCACACACTT          
 
• IP-10 forward: CTGCCGTCATTTTCTGCCTC 
• IP-10 reverse:  CACTGGCCCGTCATCGATAT 
 
• MCP-1 forward: CAGCAGCAGGTGTCCCAAA 
• MCP-1 reverse:  TGTCTGGACCCATTCCTTCTTG 
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• MIP1α forward: TTTTGAAACCAGCAGCCTTTG 
• MIP1α reverse:  TTGGAGTCAGCGCAGATCTG 
 
GENERATION OF BM-DERIVED DCs 
BM-derived DCs were generated as described (154). Briefly, BM-donor mice were euthanised 
using CO2 and the femurs and tibia were removed. BM-cells were isolated by flushing the 
bones with PBS and were filtered through a 100μm cell strainer. Cells (2-2.5x106 in 10 ml) 
were cultured in RMPI containing 10% FCS with the addition of 10% conditioned RPMI 
medium obtained from the culture of GM-CSF-transfected X-63 cells (obtained from A. 
Rollink, University of Basel, Switzerland). After at least 6 days, BM-derived DCs were 
matured with 10 μg/ml LPS overnight while immature BM-derived DCs were maintained in 
GM-CSF-containing medium. BM-derived DCs were used from days 7 to 9.  
 
T CELL PROLIFERATION 
Tg T Cell Proliferation and Polarisation 
For in vitro proliferation of transgenic T cells, spleens were harvested from naïve OT-II mice 
and CD4+ T cells were purified using BD-IMag magnetic beads (BD Pharmingen). The purity 
of T cell isolation was verified by FACS analysis. 1x105 OT-II T cells were cultured in a 96-
well plate together with 3,000-10,000 immature or mature BM-DCs. Prior to co-culture, BM-
DCs were pulsed with 1 μg/ml OVA protein (Sigma) in RPMI for 3 hours, followed by 
washing and irradiation with 2000 rads. Non-pulsed DCs were used as a control as well as T 
cells cultured alone. Cells were incubated for 4 days and 3[H]-thymidine was added for the 
last 18 hours of culture. 
For in vivo polarisation of TCR Tg cells, mice were injected with 25x106 OT-II splenocytes 
and immunized by bilateral flank injection of 200μg OVA protein emulsified in CFA. After 5 
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days, mice were killed and LN cells were isolated and incubated for 5 hours with 50 ng/ml 
phorbol 12-myristate 13-acetate (PMA), 500 ng/ml ionomycin and Golgiplug (BD 
Pharmingen). Cells were permeabilised with the Cytofix/Cytoperm Kit (BD Pharmingen) 
according to the manufacturer’s protocol and stained with anti-IL-17, anti-IFNγ antibodies 
and an antibody against the OT-II Tg TCR, anti-Vα2, prior to cytofluorometric analysis. 
 
Mixed Lymphocyte Reaction 
To assess proliferation of allogeneic CD4+ T cells, spleen and LNs were harvested from 
Balb/c mice and CD4+ T cells were purified using BD-IMag magnetic beads (BD 
Pharmingen). 1x105 CD4+ T cells in complete RPMI were added to a 96-well plate. Mature 
and immature BM-DCs were washed, resuspended in RPMI at various concentrations and 
added to the CD4+ T cells in triplicate. The MLR assay was incubated for 4 days at 37°C and 
3[H]-thymidine was added for the last 18 hours of culture.  
 
MIGRATION ASSAYS 
Migration assays were performed to analyse the migration capacities of neutrophils of DCs 
isolated from wt, IL-18-/- and IL-18Rα-/- mice. For isolation of neutrophils, mice were injected 
i.p. with 1 ml of 3% (w/v) Brewer’s thioglycollate medium (Difco). To remove peritoneal 
exudates cells, the peritoneal cavity was flushed with 10 ml HBSS (without Ca2+ and Mg2+) 
containing 1% BSA and 10 mM EDTA 20 hours post-injection. Cells were collected by 
centrifugation and Fc block (anti-CD16; BD Pharmingen) was added to the cells prior to 
FACS staining with anti-GR1 and anti-CD11b antibodies. Stained cells were filtered through 
a 50 μm mesh and neutrophils were FACS sorted for by gating on the double-positive GR1, 
CD11b population.  
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Sorted neutrophils were resuspended at 1x106 cells/ml in X-vivo 15 medium 
(Biowhittaker/Cambrex) and 100 μl of the cell suspension was seeded into a transwell insert 
(Costar). The insert was added to a 24-well plate containing medium or the chemoattractant 
fMLP (end conc 10-6 M; Sigma). Cells were incubated for 60 min at 37°C and after 
incubation the remaining cells on the upper membrane were removed with a cotton swab. The 
migrated cells, attached on the lower part of the membrane, were stained for 20 min at 37°C 
with 1μM DAPI (Molecular Probes) in PBS and then fixed in 4% PFA. Migrated cells were 
counted with a square graticule (Leica Microsystems) in five visual fields per filter.  
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RESULTS 
 
Mice deficient in both IL-12p35 and IL-18 are fully susceptible to EAE 
EAE is generally referred to as a TH1-mediated disease yet deletion of IL-12p35, a major TH1-
promoting cytokine, renders mice susceptible to MOG-peptide-induced EAE (129). Shi et al. 
have demonstrated, however, that mice deficient in IL-18, a cytokine that synergises with IL-
12 in TH1 polarisation, are resistant to EAE (84). To assess whether IL-18 is capable of 
compensating for the loss of IL-12 in p35-/- mice, rendering them EAE susceptibility, we 
generated mice deficient in both IL-12p35 and IL-18 (p35-/-x IL-18-/-). Immunisation with 
MOG35-55 emulsified in CFA showed that p35-/-x IL-18-/- mice are fully susceptible to EAE 
and have a similar disease severity and development as is seen in wt mice (Fig. 1a and Table 
1). This demonstrates that IL-18 is not responsible for the EAE susceptibility of IL-12p35-/- 
mice and implies that IL-18 itself is a cytokine that has little or no effect on EAE 
pathogenesis. To confirm this, we actively immunised wt and single-mutant IL-18-/- mice with 
MOG peptide and found that IL-18-/- mice are indeed fully susceptible to EAE (Fig. 1b and 
Table 1).  
a)         b) 
 
 
 
 
 
 
 
 
Figure 1: IL-18 is not required for EAE induction. EAE was induced by subcutaneous 
immunisation with MOG35-55 emulsified in CFA. Data display the mean EAE score of each 
group. (a) EAE progression in p35-/-x IL-18-/- double deficient and wt mice. Shown is one 
representative of 2 experiments (n ≥ 5 mice/group). (b) EAE progression in wt and IL-18-/- 
mice. Shown is one representative of 3 individual experiments.  
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EAE disease incidence (%), mean time of disease onset (d) and mean maximum clinical 
score (± S.E.M.) of diseased mice, for wild-type, IL-12p35-/-IL-18-/-, IL-18-/- and IL-18Rα-/- 
mice in which EAE was induced by subcutaneous immunisation with MOG35-55.  
 
IL-18 knockout mice are deficient in IL-18 
Due to the fact that the development of EAE in IL-18-/- mice contradicted a previously 
published report (84), we extensively verified the targeting strategy and genotype of the mice. 
We could show that genomic DNA from IL-18-/- mice, in contrast to that of wt mice, is 
negative for the band amplifying the deleted sequence of IL-18 while being positive for the 
band amplifying part of IL-18 and the inserted neomycin cassette sequence (Fig. 2a). We also 
analysed by ELISA whether we could detect IL-18 secreted from activated splenocytes 
derived from wt and IL-18-/- mice, which showed that IL-18-/- mice are indeed completely IL-
18 deficient (Fig. 2b). In addition, we could clearly establish that IL-18 is not present in the 
CNS of IL-18-/- mice, in contrast to wt mice (Fig. 2c). Therefore the susceptibility of IL-18-
deficient mice to EAE, which is in contrast to the previously published data, did not occur due 
to the presence of a truncated yet functional form of IL-18 in these mice. 
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Figure 2: IL-18 is absent in IL-18-deficient mice. (a) IL-18-deficient tail DNA was 
amplified by PCR using primers for a sequence binding IL-18 (upper panel) or binding IL-
18 and the neomycin cassette (lower panel). Wt DNA (wt) was used as a positive control and 
water (-) as a negative control. (b) ELISA of IL-18 production by wt and IL-18-/- splenocytes 
activated with LPS and IFNγ, ConA or a combination of ConA and IFNγ or IL-12. (c) 
ELISA measuring IL-18 expression in CNS (brain and spinal cord) of MOG35-55-immunised 
wt and IL-18-/- mice 21 d.p.i.  
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IL-18 is required for Innate Immunity but not Ag-driven Immunity 
Despite the fairly conclusive evidence for the lack of IL-18 in the IL-18-deficient mice, we 
decided to test this result further by using cells isolated from IL-18-deficient mice in an 
immunoassay. As observed in many experimental systems, the deletion of IL-18 consistently 
results in the paucity of an IFNγ response (155;156). We thus stimulated lymphocytes derived 
from naïve wt, IL-18-/- and, in addition, IL-18Rα-/- mice in vitro with the lectin Concanavalin 
A (ConA) for 16 hours and IFNγ production was subsequently measured by ELISA. 
Consistent with the principle that IL-18 has an effect on IFNγ production, lymphocytes from 
both IL-18-/- and IL-18Rα-/- mice did not secrete IFNγ in contrast to wt lymphocytes (Fig. 3a). 
We could further verify that T cell function and activation during polyclonal stimulation is not 
directly impaired as there was no difference in IFNγ secretion by stimulated wt, IL-18-/- and 
IL-18Rα-/- purified CD4+ T cells (Fig. 3b). 
To establish the role of IL-18 and IL-18Rα in an adaptive Ag-driven immune 
response, we immunised wt, IL-18-/- and IL-18Rα-/- mice subcutaneously with MOG35-55 or 
with keyhole limpit hemocyanin (KLH), as a large immunogenic protein antigen (of about 
400 kilodaltons) in CFA and 7 days later isolated and restimulated lymphocytes with the 
cognate Ag in vitro. Surprisingly, when KLH was used, we did not observe a drastic 
difference in the IFNγ-producing ability of lymphocytes derived from wt, IL-18-/- and IL-
18Rα-/- mice (Fig. 3d). The less immunogenic MOG-peptide however revealed that IL-18Rα-/- 
mice produced significantly less IFNγ than wt or IL-18-/- mice (Fig. 3c). Our data support the 
notion that while IL-18 and IL-18Rα are critical co-factors for the early IFNγ response of 
mitogen-activated T cells, peptide-induced responses revealed discordant behaviour between 
lymphocytes lacking IL-18 or IL-18R. On the other hand, activation and IFNγ production 
through a complex large protein Ag appears to be independent of IL-18 or IL-18Rα, a concept 
that is in agreement with the recent report by Santos et al (157). 
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a)         b) 
 
c)        d) 
  
Figure 3: IL-18 is required for mitogen-, but not antigen-driven TH1 development. (a) 
ELISA assessing IFNγ secretion by naïve wild-type, IL-18-/- and IL-18Rα-/- lymph node 
cells, stimulated for 16 hours with 5 μg/ml ConA (+ ConA) or medium (- ConA). (b) ELISA 
for IFNγ production from CD4+ T cells purified from naïve wild-type, IL-18-/- and IL-18Rα-/-
splenocytes by magnetic cell sorting and stimulated with anti-CD3 or a combination of anti-
CD3 and anti-CD28 mAbs for 36 hours in vitro (c,d) Mice were immunised with 200 μg 
MOG35-55 or KLH in CFA and 7 days later LN cells were isolated and restimulated. (c) 
ELISA of IFNγ in supernatant from MOG35-55 immunised mice restimulated in duplicate 
with 50 μg/ml MOG35-55 (+ MOG) or medium (- MOG) for 48 hours. (d) ELISA of IFNγ in 
supernatant from KLH-immunised mice restimulated in duplicate with 50 μg/ml KLH (+ 
KLH) or medium (- KLH) for 48 hours. Error bars represent ± S.E.M. Data are 
representative of at least 2 individual experiments and combine 2 mice in each group. 
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IL-18Rα-/- mice are resistant to EAE  
Mice deficient in IL-18Rα have been described as having an immunological phenotype 
similar to that of IL-18-/- mice (158). Given the discordant behaviour of IL-18- and IL-18Rα-
deficient lymphocytes towards MOG-peptide in recall-responses, we discovered that IL-18Rα-
/- mice were, in sharp contrast to both wt and IL-18-/- mice, resistant to EAE induction (Fig. 
4a and Table 1). To ensure the absence of a truncated form of IL-18Rα in the IL-18Rα-/- 
mice, we tested for its presence in blood using an antibody specific for the extracellular, non-
deleted part of the molecule. This showed that there was no IL-18Rα expression on cells from 
IL-18Rα-deficient mice (Fig. 4b). Histological analysis of spinal cords obtained 28 days after 
EAE induction showed that EAE-susceptible wt and IL-18-/- mice incur significant 
inflammation and demyelination as revealed by H&E and LFB staining, respectively (Fig. 
5a). A more detailed analysis demonstrated the infiltration of T cells, macrophages and B 
cells and axonal damage in the CNS of these mice (Fig. 5a and Fig. 5b). In contrast, IL-18Rα-
/- samples demonstrated no leukocyte infiltration or demyelination (Fig. 5a and Fig. 5b). 
Quantitative RNA analysis of spinal cords from mice with EAE showed that in accordance 
with the presence of inflammatory infiltrates, wt and IL-18-/- mice had increased expression of 
chemokines and inflammatory cytokines while these were decreased or absent in IL-18Rα-/- 
mice (Fig. 6).  
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a)          b) 
 
 
 
 
 
 
Figure 4: Discordant EAE progression in IL-18-/- and IL-18Rα-/- mice. (a) EAE was 
induced in wt, IL-18-/- and IL-18Rα-/- mice by subcutaneous immunisation with MOG35-55. 
Data display the mean EAE score of each group. Shown is one representative of 3 individual 
experiments. (b) Flow cytometry measuring expression of IL-18Rα, using an extracellular-
binding anti-IL-18Rα Ab, in the blood of wt and IL-18Rα-/- mice. Shown is one 
representative of 3 individual mice. 
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a)  
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b)  
 
 
 
 
 
 
Figure 5: Histopathological analysis of IL-18-/- and IL-18Rα-/- mice.  (a) Paraffin-
embedded spinal cord sections from PBS-perfused wt, IL-18-/-, IL-18Rα-/- and naive wt 
animals on day 28 after induction of EAE with MOG35-55. Haematoxylin and eosin (H&E) 
assesses cell infiltration, luxol fast blue (LFB) assesses demyelination and CD3+, MAC3+ 
and B220 stainings demonstrate T cell, macrophage and B cell infiltration, respectively. 
Scale bar, 200μm. (b) Quantification of CD3+, MAC3+, B220+ and APP+ cells in histological 
sections of spinal cord from actively immunised wt (n=8), IL-18-/- (n=5) and IL-18Rα-/- 
(n=4) mice 28 days post-immunisation. 
 
 
 
Figure 6: Analysis of cytokine and chemokine expression in the CNS of MOG35-55-
immunised mice. Chemokine and inflammatory cytokine mRNA expression in the spinal 
cords of MOG35-55-immunised wt, IL-18-/- and IL-18Rα-/- mice was analysed 14 days post-
immunisation by real-time PCR. Naïve spinal cord was analysed as a negative control. Error 
bars represent ± S.E.M. Data are representative of at least 2 individual experiments and 
combine 2 mice in each group. 
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Anti-IL-18Rα mAb-treated mice are resistant to EAE 
The discordant behaviour of IL-18-/- and IL-18Rα-/- mice with regards to EAE strongly points 
towards an additional IL-18Rα ligand with powerful encephalitogenic properties. In order to 
verify that IL-18Rα and IL-18 have independent biological functions, we blocked IL-18Rα in 
EAE-susceptible IL-18-/- mice. Treatment of IL-18-/- mice with anti-IL-18Rα monoclonal Abs 
(mAb), given 1 day pre-immunisation and every 3 days thereafter until the end of the 
experiment, significantly reduced disease development (Fig. 7a). Administration of anti-IL-
18Rα mAbs did not lead to deletion of IL-18Rα-expressing cells nor did it alter the 
composition of peripheral leukocytes in the blood, LN or spleen (Table 2). Interestingly, 
treating IL-18-/- mice with mAbs against IL-18Rα post-immunisation (day 10 p.i.) also 
abrogated EAE progression (Fig. 7b) suggesting that IL-18Rα engagement is an important 
event during the effector phase of EAE. Combining the facts that IL-18Rα blockade prevents 
EAE even in mice in which its ligand is completely removed by gene-targeting and that IL-18 
has a reportedly low affinity to IL-18Rα, we propose that another ligand must be responsible 
for the engagement, signalling and immune development mediated by IL-18Rα.  
a)                                                 b) 
 
 
 
 
 
 
 
 
Figure 7: Anti-IL-18Rα Ab treatment abrogates EAE development and progression. 
(a) IL-18-/- mice were treated with 450 μg anti-IL-18Rα Ab or control IgG 1 day pre-
immunisation with MOG35-55 and with 300 μg antibody for every 3 days thereafter. (b) IL-
18-/- mice were immunised and treated with 300 μg anti-IL-18Rα Ab or control IgG at the 
first sign of disease. Shown are representatives of at least two individual experiments (n ≥ 5 
mice/group).  
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IL-18-/- mice were subcutaneously immunised with MOG35-55 and treated with anti-IL-18Rα 
mAb or IgG. The composition of leukocytes in LNs, spleen and blood was analysed 7 days 
later by flow cytometry. Shown is the percentage of leukocytes and accessory cells in LNs, 
which is representative of spleen and blood. 
 
 
CNS-specific IL-18Rα deletion does not affect the development of EAE 
By administering anti-IL-18Rα antibodies to IL-18-/- mice, we were able to abrogate EAE 
development, even when the antibodies were given at the time of disease onset. The CNS 
micro-environment is critical for the ongoing inflammatory response that occurs in MS and 
EAE. Through the production of cytokines and chemokines by CNS-resident cells, such as 
microglia, immune cells are attracted into and are reactivated in the CNS. We therefore 
sought to determine if IL-18Rα expression on CNS-resident cells is crucial for EAE 
development. To do so, we generated bone marrow chimeric mice by lethally irradiating wt or 
IL-18Rα-/- recipients and reconstituting them with BM from either wt of IL-18Rα-/- donor 
mice. This produced the following groups of mice that confined IL-18Rα to either the 
peripheral or CNS compartment: wt → IL-18Rα-/- and IL-18Rα-/- → wt. For a positive control, 
wt → wt mice were also generated. Immunisation of the BM-chimeric mice demonstrated that 
while mice with IL-18Rα-/- CNS but a wt immune system are completely susceptible to EAE 
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(wt → IL-18Rα-/-), expression of IL-18Rα-/- in the peripheral immune compartment is an 
absolute requirement for the development of disease (IL-18Rα-/- → wt) (Fig. 8).  
 
 
 
 
 
 
 
 
Figure 8: IL-18Rα expression in the CNS is not required for EAE pathogenesis. EAE 
progression in WT → WT, WT → IL-18Rα–/– and IL-18Rα–/– → WT BM-chimeric mice 
actively immunised with MOG35-55 peptide. Shown is one representative of 2 individual 
experiments (n ≥ 5 mice/group). 
 
 
 
IL-18Rα-/- CD4+ T cells are not defective in activation marker upregulation 
IL-12p35-/- mice have a defective TH1 response, characterised by decreased levels of IFNγ 
production, and are hypersusceptible to MOG35-55-induced EAE. We were able to determine 
that MOG-reactive lymphocytes from IL-18Rα-/- mice were, in contrast to those from wt and 
IL-18-/- mice, also deficient in IFNγ production (Fig. 3c). However, in contrast to IL-12p35-/- 
mice, IL-18Rα-/- mice were almost completely resistant to EAE induction (Fig. 4a). 
Therefore, EAE resistance of IL-18Rα-deficient mice does not result from defective IFNγ 
production alone. CD4+ T cells are known to have a critical role in autoimmune inflammation 
and the expression of specific cell-surface markers by these cells can determine their ability to 
induce or down-regulate an autoimmune response. CD62L (L-selectin) is an integrin that 
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regulates the homing and entry of T cells into the LNs and, as such, the expression of CD62L 
is decreased from the surface of T cells during T cell activation. In contrast, other integrins 
such as VLA-4, which binds VCAM-1 on endothelial cells and is required for entry into the 
target organ, and CD162 (PSGL-1) are increased on the surface of Ag-reactive T cells. The 
levels of another marker, CD5, are critical for determining the responsiveness and survival of 
T cells after Ag stimulation. T cells with elevated levels of CD5 develop Ag-specific 
unresponsiveness whereas CD5-/- T cells are hyper-responsive leading to activation-induced 
cell death (AICD). Furthermore, deletion of CD5 in mice results in their protection from EAE 
(159). Therefore we wondered if the protection of IL-18Rα-/- mice to EAE resulted from 
abnormal levels of CD5 or activation marker expression on the surface of activated CD4+ T 
cells. To do so, we harvested LN cells from KLH-immunised wt, IL-18-/- and IL-18Rα-/- mice 
7 d.p.i. and restimulated them in vitro for 2 days with the cognate Ag. We then looked at the 
ability of these cells to express the surface markers CD62L, CD162, VLA-4 and CD5 by 
incubating them with Abs against these markers and analysing their expression by flow 
cytometry. We could show that there is no difference in the expression of these activation 
markers in wt, IL-18-/- and IL-18Rα-/- CD4+ T cells and therefore defective CD4+ T cell 
activation does not explain the resistance of IL-18Rα-/- mice to EAE (Fig. 9). 
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Figure 9: IL-18Rα-/- CD4+ T cells upregulate activation markers. Wt, IL-18-/- and IL-
18Rα-/- mice were immunised s.c. with KLH and 7 d.p.i., LN cells were harvested and 
restimulated in vitro. After 2 days restimulation, the expression of activation markers on 
CD4+ T cells was analysed by FACS analysis. 
        Wt             IL-18-/-               IL-18Rα-/- 
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IL-18Rα deficiency does not affect regulatory T cell numbers 
Regulatory T cells have an important function in suppressing the proliferation of self-reactive 
T cells (50) and it has been demonstrated that the transfer of Tregs can prevent the induction 
of EAE in a spontaneously-occurring mouse model (160). We thus decided to analyse the 
effect of IL-18R-deficiency on circulating numbers of Tregs in the blood, LN and spleen. 
FACS analysis of these organs showed that the percentage of Tregs found in the LNs (as 
representative) of naïve (Fig. 10a) or MOG35-55-immunised (Fig. 10b) mice does not differ 
between wt, IL-18-/- and IL-18Rα-/- mice. 
 
a) 
 
 
 
 
 
b) 
 
 
 
 
 
Figure 10: Regulatory T cells are not increased in EAE-resistant IL-18Rα-/- mice. LN, 
spleen and blood were isolated from naïve or MOG35-55-immunised mice 14 d.p.i. and 
stained with anti-CD4 and anti-CD25 antibodies. The percentage of regulatory T cells was 
analysed by FACS analysis. Shown is the number of CD4+CD25+ T cells present in LNs, 
which is representative of both spleen and blood. 
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IL-18Rα deficiency does not affect inflammatory cell migration 
EAE is characterised by a massive influx of inflammatory cells into the CNS at the peak of 
disease yet immune cells also invade the CNS prior to the onset of clinical symptoms 
(161;162). For example, recruitment of CD4+ T cells into the CNS is critical for the initiation 
of the effector phase of EAE while invasion of polymorphonuclear leukocytes appears to have 
a role in orchestrating these events (163). Neutrophils constitutively express IL-18R and 
activation of the receptor results in enhanced adhesion molecule and chemokine expression 
(85). Furthermore, IL-18R expression was shown to be important for the migration of 
plasmacytoid DCs. Therefore to establish the effect of IL-18Rα on cellular migration, we 
isolated peritoneal infiltrates from wt, IL-18-/- and IL-18Rα-/- 24 hours after intraperitoneal 
injection of 3% thioglycollate and sorted for CD11b+ and GR1+ cells in order to obtain 
neutrophils. The capacity of neutrophils to migrate towards the chemoattractant fMLP was 
subsequently tested in vitro, which demonstrated that IL-18Rα-/- neutrophils migrated to the 
same extent as those from wt and IL-18-/- mice (Fig. 11). 
 
 
 
 
 
 
 
Figure 11: IL-18Rα deficiency does not affect neutrophil migration. Peritoneal 
neutrophils were isolated from the peritoneal exudates of wt, IL-18-/- and IL-18Rα-/- mice by 
cell sorting. Neutrophils were plated in an insert that was placed into a well containing either 
10-6 M fMLP or medium. After 1 hour, the well insert was removed, fixed and the number of 
migrated neutrophils counted using a binocular.  
 
 
 59
IL-18Rα engagement is required for the persistence of inflammatory cells during the 
effector phase of disease  
Although no difference in migratory capacity of neutrophils could be seen in an in vitro assay, 
we could not rule out that the IL-18Rα-deficiency affects cell migration in vivo. Therefore, to 
establish the impact of IL-18Rα on the capacity of inflammatory cells to invade the CNS at 
time-points of pre-clinical disease, we immunised mice and analysed the CNS for 
inflammatory infiltrates on day 7 post-immunisation by flow cytometry. In contrast to peak 
disease when the IL-18Rα-/- CNS is devoid of inflammatory infiltrates (Fig. 5), IL-18Rα-/- 
leukocytes (CD45-high cells) were capable of CNS infiltration to the same extent as those of 
wt and IL-18-/- mice at stages of pre-clinical disease (Fig. 12a). Detailed analysis of the 
invading cells showed that comparable numbers of CD4+ T cells, granulocytes, macrophages 
and B cells were present in all three strains (Fig. 12b). As IL-18Rα-/- inflammatory cells are 
absent from the CNS during clinical disease, it seems that IL-18Rα-/- inflammatory cells do 
not persist during the effector phase of the disease. Such results resemble those obtained with 
IL-23p19-deficient mice and IL-23p40-deficient mice, which are also resistant to MOG35-55-
induced EAE and in which inflammatory cells are found in the CNS early after immunisation 
but before disease begins (56).  
 Given the similarities between IL-18Rα-/- and IL-23-/- mice regarding their EAE 
resistance with concomitant inflammatory cell invasion into the CNS, we assessed the impact 
of IL-18Rα on IL-17 production. IL-17 producing TH cells (TH17) are now widely accepted to 
be the main pathogenic population during autoimmune inflammation (56;143). We therefore 
quantified the number of IL-17 producing MOG-reactive T cells invading the CNS before and 
after clinical disease onset in mice immunised with MOG35-55. ELISpot analysis revealed that 
immediately prior to disease onset (9 days after immunisation), the number of MOG-specific 
IFNγ-secreting cells invading the CNS was similar in EAE-susceptible IL-18-/- and EAE-
resistant IL-18Rα-/- mice, whereas TH17 cells were nearly completely absent from the CNS of 
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IL-18Rα-/- mice only (Fig 12c). After disease onset, moreover, although we detected increased 
numbers of IFNγ- and IL-17-secreting cells in the susceptible IL-18-/- and wt mice, these cells 
were almost completely absent from the CNS of IL-18Rα-/- mice (Fig. 12d).  
a)       b) 
 
 
 
 
 
c)       d) 
 
 
 
 
 
 
 
 
Figure 12: Tissue invasion at pre-clinical stages is not affected by IL-18Rα. (a,b) Flow 
cytometry of CNS-derived leukocytes from MOG35-55-immunised wt, Il-18-/- and Il-18Rα-/- 7 
days after immunisation; cells were stained with anti-CD45, anti-CD11b anti-GR1, anti-
B220 and anti-CD4 antibodies. (a) Percent CD45hi infiltrating cells in the CNS (indicated by 
numbers above bracketed lines). (b) CD45hi cells were gated and percentages of infiltrating 
macrophages, granulocytes, B cells and CD4+ T cells were assessed. Naïve, non-immunised 
mice were used as a negative control. Shown is one representative of 3 individual 
experiments with 2 mice per experiment. (c,d) ELISpot analyses for IFNγ and IL-17 
production from CNS-derived MOG-reactive lymphocytes restimulated for 18-20 hours with 
MOG35-55. (c) 9 dpi pre-disease onset; (d) 14 dpi post-disease onset. Data in the bar graphs 
represent at least 2 individual experiments and combine 2 mice in each group. Shown is the 
mean ± S.E.M.  
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IL-18Rα engagement is required for TH17 cell polarisation 
To determine whether IL-18Rα-/- mice are defective in generating IL-17-producing T cells, we 
analysed IL-17 expression by freshly primed lymphocytes in vitro. We immunised wt, IL-18-/- 
as well as IL-18Rα-/- mice with either MOG35-55 peptide or KLH and collected lymphocytes 
from the draining LNs after 7 days. By performing real-time PCR analysis of mRNA obtained 
from lymphocytes after restimulation with their cognate Ag, we found that the expression of 
IL-17 mRNA was significantly lower in IL-18Rα-/- cells than in wt or IL-18-/- cells (Fig 13a). 
We corroborated those results by ELISA of cell culture medium of lymphocytes rechallenged 
with their cognate Ag in vitro, which demonstrated that IL-17 production was significantly 
decreased in IL-18Rα-/- but not IL-18-/- lymphocytes (Fig. 13b). In contrast to the production 
of IFNγ, which shows some dependence on the immunogenicity of the Ag, IL-17-secretion 
was consistently lower in the IL-18Rα-/- leukocytes, even when KLH was used as the driving 
Ag. Thus, the resistance of IL-18Rα-/- mice to EAE could certainly derive from their inability 
to generate sufficient numbers of inflammatory TH17 cells. 
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Figure 13: TH17 induction is dependent on IL-18Rα but not IL-18. (a) Real-time PCR 
analysis of IL-17 mRNA expression by wt, IL-18-/- and IL-18Rα-/- lymphocytes from mice 
immunised 7 days previously and restimulated for 48h with 50 μg/ml MOG35-55 or KLH. 
Data are representative of 2 individual experiments combining at least 2 mice per group. 
Shown is the mean ± S.E.M. Results are normalized to β-actin expression and analysed in 
duplicate. (b) ELISA of IL-17 protein expression by MOG35-55 and KLH-restimulated 
lymphocytes, analysed in duplicate. 
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Expression of IL-18Rα on accessory cells is essential for encephalitogenicity 
The results thus far show that IL-18Rα-deficiency completely prevents the development of 
EAE and TH17 polarization, whereas IL-18 appears to be irrelevant for both phenotypes. The 
cell type on which the IL-18Rα exerts its primary effects remains unknown. This is due 
mainly to the fact that IL-18Rα  is expressed by various cell types and tissues (83-85). In 
order to identify which cells are required to express IL-18Rα, we selectively expressed IL-
18Rα on cells in the leukocyte compartment using irradiation bone-marrow (BM) chimeras. 
Following irradiation and reconstitution, the immune compartment in secondary lymphoid 
tissues of recipient mice is comprised of hematopoietic cells derived from donor mice 
(11;153). We generated BM chimeras by transferring either a 4:1 ratio of Rag1-/- and IL-
18Rα-/- BM into wt recipients (Rag1-/- + IL-18Rα-/- → WT) or IL-18Rα-/- BM only into wt 
recipients (IL-18Rα-/- → WT); as a control, we also transferred wt BM into wt recipients (WT 
→ WT). Because Rag1-/- mice do not have lymphocytes, all lymphocytes from the 4:1 Rag1-/- 
+ IL-18Rα-/- → WT chimera were IL-18Rα-deficient, whereas the majority of all other non-
lymphocyte leukocytes (accessory cells such as neutrophils, eosinophils, etc.) expressed IL-
18Rα. 
As anticipated from our previous data, IL-18Rα-/- → WT chimeric mice were resistant 
to EAE after immunisation with MOG peptide (Fig. 14a). However, addition of Rag1-/- BM to 
the IL-18Rα-/- BM (Rag1-/- + IL-18Rα-/- → WT) resulted in susceptibility to EAE (Fig. 14a). 
Thus, IL-18Rα expression on accessory cells is sufficient for EAE induction even when 
lymphocytes are IL-18Rα-deficient. 
To confirm the role and function of IL-18Rα signalling on accessory cells during the 
effector phase of EAE, we adoptively transferred encephalitogenic MOG-reactive T cells 
derived from wt donor mice into both wt and IL-18Rα-/- recipient mice. Fully primed and 
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activated encephalitogenic T cells derived from wt mice induced EAE in wt recipient mice, 
yet they were incapable of inducing clinical EAE in IL-18Rα-deficient hosts (Fig. 14b). 
 
a)          b) 
 
 
 
 
 
 
Figure 14: IL-18Rα-deficiency specifically affects non-lymphocytic leukocytes. (a) EAE 
progression in IL-18Rα–/– → WT, IL-18Rα–/– + Rag1–/– → WT and WT → WT BM-
chimeric mice actively immunised with MOG35-55 peptide. Shown is one representative of 2 
individual experiments (n ≥ 5 mice/group). (b) EAE was induced in recipient mice by the 
adoptive transfer of 25 x 106 MOG-reactive lymphocytes into IL-18Rα–/– and wt mice. 
Shown is one representative of 2 individual experiments (n ≥ 5 mice/group). 
 
IL-18Rα expression on DCs is not necessary for naïve T cell priming 
As IL-18Rα has been demonstrated to be present on myeloid cells (164), such as APCs which 
play an important role in T cell activation, we next tested the capacity of IL-18Rα-deficient 
APCs to prime naïve T cells. To do so, we carried out a mixed lymphocyte reaction (MLR) 
whereby CD4+ T cells were purified from BALB/c mice and cultured for four days with wt, 
IL-18-/- or IL-18Rα-/- immature or mature BM-derived DCs. Measurement of their 
proliferation by thymidine incorporation showed no difference in the stimulatory abilities of 
mature (Fig. 15a) or immature (Fig. 15b) IL-18Rα-/- BM-DCs. Testing this in a transgenic 
system, we similarly purified CD4+ T cells from 2d2 mice that express a transgenic TCR 
specific for MOG35-55 and co-cultured them with mature, MOG-peptide-pulsed wt, IL-18-/- 
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and IL-18Rα-/- BM-derived DCs. Again, we found no difference in the ability of the different 
DCs to stimulate proliferation of the 2d2 T cells (Fig. 15c). To confirm this in an in vivo 
setting, we injected carboxyfluorescein diacetate succinimidyl diester (CFSE) labelled-2d2 
cells into wt, IL-18-/- and IL-18Rα-/- mice, immunised them with MOG35-55 and analysed 
proliferation of 2d2 cells by flow cytometry after 4 days. Again, there was no difference in the 
proliferation of 2d2 cells in wt, IL-18-/- or IL-18Rα-/- mice (Fig. 15d). However, additional 
experiments using the adoptive transfer of CD4+ T cells expressing a transgenic TCR specific 
for the immunodominant epitope of OVA confirmed that IL-18Rα deficiency on non-
lymphocytic leukocytes reduces the generation of TH17 cells (Fig. 15e).  
Despite no obvious defect in the ability of IL-18Rα-/- APCs to induce T cell expansion, 
we tested the expression of costimulatory molecules, such as CD40, CD80 and CD86, by 
LPS-stimulated splenic DCs. Confirming the normal T cell proliferative responses, we could 
detect no difference in the expression of these molecules by wt, IL-18-/- and IL-18Rα-/- DCs 
(Fig. 16a). 
With regards to the ability of myeloid cells to reach the CNS tissue, we generated 
mixed BM chimeras of CD45 congenic wt and IL-18Rα-/- BM-donors into WT recipients and 
evaluated the capacity of myeloid populations to invade the CNS during disease. We first 
confirmed that the mice had a 1:1 ratio of WT and IL-18Rα-/- hematopoietic cells in peripheral 
blood and spleen. After EAE induction, we found both CD45.1 and CD45.2 myeloid 
populations in the CNS at a 1:1 ratio, indicating that there was no migratory difference 
between the two genotypes of myeloid cells (Fig. 16b).  
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c)           d)  
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Figure 15: IL-18Rα-deficiency on accessory cells does not affect naïve T cell priming. 
(a,b) Proliferation of BALB/c CD4+ T cells cultured with (a) mature and (b) immature BM-
derived DCs from wt, IL-18-/- and IL-18Rα-/- mice. (c) Proliferation of MOG35-55 TCR 
transgenic (2d2) CD4+ T cells stimulated with BM-derived DCs from wt, IL-18-/- and IL-
18Rα-/- mice, matured with 10 μg/ml LPS and subsequently pulsed with 1 μg/ml MOG 
peptide. Error bars, S.E.M., n=2 mice per group. (d) Flow cytometry of in vivo proliferation 
of CFSE-labelled 2d2-transferred cells into MOG35-55-immunised wt, IL-18-/- and IL-18Rα-/- 
mice and a non-immunised control mouse. Data are representative of at least two 
experiments with at least two mice per experiment. (e) Flow cytometry of intracellular 
cytokine staining of lymphocytes from OVA-immunised mice injected with OTII 
splenocytes 4 days earlier. Numbers in quadrants indicate the percent of cells staining 
positive for the indicated cytokines. 
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Figure 16: IL-18Rα-deficient DCs are activated and migrate to the CNS. (a) Flow 
cytometry of wt and IL-18Rα-/- splenocytes after overnight stimulation with LPS. Cells are 
stained with anti-CD40, anti-CD80 and anti-CD86 antibodies and gated on CD11c-positive 
cells. (b) Flow cytometry of CNS from CD45.1 hosts, reconstituted with a 1:1 mix of 
CD45.2 wt and CD45.1 wt or CD45.1 IL-18Rα-/- BM, 14 days post-immunisation with 
MOG35-55. Data are representative of at least 2 experiments. 
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IL-18Rα-deficient APCs show limited IL-12/23p40 secretion required for pathogenic 
TH17 cell generation 
As restimulation with cognate Ag demonstrated a significant decrease in IL-17 production, we 
decided to analyse the capacity of APCs to secrete IL-12/23p40, which is necessary for the 
polarisation of pathogenic TH17 cells. To determine p40 secretion, we stimulated T cell-
depleted splenocytes with anti-CD40 mAb for 36 hours before analysing p40 production by 
ELISA. We found that in contrast to high levels of p40 production by wt and IL-18-/- APCs, 
IL-18Rα-/- APCs, like p40-/- APCs, showed impaired p40 production (Fig. 17a). Finally, we 
could validate the deficient IL-12/23p40 production in an adaptive immune response by 
restimulating lymphocytes from MOG- and KLH-immunised mice in vitro and analysing p40 
production after 2 days. As expected, there was a significant decrease in the production of p40 
by IL-18Rα-/- lymphocytes as opposed to wt and IL-18-/- lymphocytes (Fig. 17b,c). The effect 
of IL-18Rα on IL-23 production is specifically related to IL-23p40 upregulation as the 
production of IL-23p19 by MOG35-55-restimulated LN cells was similar in wt, IL-18-/- and IL-
18Rα-/- mice (Fig. 17d). Our data indicate that APC activation results in the production of an 
IL-18Rα ligand driving IL-23 secretion by APCs. Therefore the resistance of IL-18Rα-/- mice 
to EAE seems to result from abrogated TH17 cell development, which is a consequence of 
poor p40 production by IL-18Rα-/- APCs.   
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Figure 17: IL-18Rα engagement promotes the production of IL-23p40 but not IL-
23p19. (a) ELISA of IL-12, -23 p40 production in the supernatant of T-cell depleted naive 
wt, IL-18-/- and IL-18Rα-/- splenocytes stimulated with 5 μg/ml anti-CD40 mAb for 36 
hours. (b,d) Wt, IL-18-/- and IL-18Rα-/- mice were immunised with MOG35-55 in CFA and 
LN cells were isolated 7 days later and restimulated with 50μg/ml MOG35-55 or medium for 
48 hours. (b) ELISA of p40 expression in supernatant. (c) ELISA of p40 expression in 
supernatant of LN cells from wt, IL-18-/- and IL-18Rα-/- mice immunised with KLH in CFA, 
isolated 7 days later and restimulated with 50μg/ml KLH or medium for 48 hours. (d)  Real-
time PCR analysis of p19 mRNA expression. Shown is the mean ± S.E.M. Data are 
representative of 2 individual experiments combining at least 2 mice per group. 
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DISCUSSION 
 
Organ-specific inflammatory diseases generally result from inappropriate expansion and 
activation of effector T lymphocytes, which have escaped peripheral tolerance and react to 
expressed self-antigens. Until recently, TH1 lymphocytes were thought to represent the auto-
reactive T cells responsible for inducing cellular autoimmunity (92;93;165-167). However, 
mounting evidence indicates that TH17 cells, and not TH1 cells, are the pathogenic T cell 
effectors in autoimmunity and that their development is negatively regulated by both TH1 and 
TH2 cytokines (51;56;127;129;132;143;168).  
 
IL-18 is not required for EAE pathogenesis 
We were interested in characterising the role of IL-18 in EAE. IL-18 synergises with IL-12 in 
the differentiation of naive TH cells into TH1 cells. Contrary to initial findings, confused by 
the use of IL-12p40 as a target, it is now accepted that IL-12 is not pathogenic during 
autoimmune inflammation. Our initial goal was then to determine if EAE susceptibility of IL-
12-deficient mice occurs as a result of redundancy, whereby the continued presence and 
activity of IL-18 in these mice is sufficient for EAE induction. Our data challenge that 
hypothesis as IL-12p35-/-IL-18-/- double deficient mice were fully susceptible to EAE (Fig. 
1a). We also found that single-mutant IL-18-/- mice are susceptible to EAE and are not 
defective in IFNγ production during cognate Ag recall responses (Fig. 1b and Fig. 3). These 
results contrast with previously published data showing that IL-18-/- mice are resistant to EAE 
(84) and are deficient in mounting auto-reactive TH1 responses (84). The defective TH1 cell 
response was suggested to result at least in part from abrogated IFNγ production by NK cells, 
as the transfer of NK cells from recombination activating gene (RAG)-deficient, but not from 
IFNγ-/-, mice was able to rescue the susceptibility of these mice to EAE. As we could clearly 
demonstrate that the mice we used are deficient in IL-18 (Fig. 2), the discrepancy between our 
data and the earlier study could be explained by a different health status of the mice or their 
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degree of backcrossing onto the C57BL/6 background. Our results with the IL-18-/-  mice are 
also in agreement with subsequent data with independently derived IL-18-/- mice that show 
susceptibility to experimental autoimmune uveitis (EAU) after using a similar methodology as 
was used in our study (169;170). Thus, IL-18-/- mice are susceptible to EAE and EAU by the 
standard methodology of inducing experimental autoimmunity. Other more recent reports also 
support our findings for a non-pathogenic role for IL-18 in autoimmunity. Santos et al 
demonstrated that IL-18 is unnecessary during Ag-induced TH1 responses and is redundant in 
an Ag-induced arthritis model (157), which is in contrast to previous findings showing that 
IL-18 is required for the induction of CIA. They suggest that differences in the pathogenic 
mechanisms of these models or genetic background of the mice could explain the conflicting 
results. Meanwhile, another group has shown that IL-18 is unnecessary for the development 
of clinical symptoms in experimental autoimmune neuritis (EAN), which contradicts previous 
results demonstrating that an antibody against IL-18 ameliorates the clinical symptoms of 
EAN (171;172). Therefore, there is an emerging non-pathogenic role for IL-18 in 
autoimmunity, which is in line with both our results and the changing Th1/Th2 paradigm.  
 
IL-18Rα engagement is crucial for EAE pathogenesis 
Despite the susceptibility of IL-18-/- mice, we found that IL-18Rα-/- mice are resistant to EAE 
(Fig. 4a), which implies that an IL-18Rα-binding ligand other than IL-18 has 
encephalitogenic properties. The affinity of IL-18 to IL-18Rα is known to be weak and 
requires the presence of IL-18Rβ for increased affinity and signalling. In addition, there are a 
number of orphan receptors within the IL-1R superfamily and given the fact that this family 
of receptor subunits form heterodimers with one another (173), it is possible that IL-18Rα not 
only has different binding partners but also different ligands. We demonstrated the importance 
of IL-18Rα by significantly attenuating disease development in IL-18-/- mice using IL-18Rα 
antibodies (Fig. 7). Given that the known IL-18Rα-ligand, IL-18, was not present in these 
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mice, that result provides persuasive evidence for the existence of an alternative IL-18Rα 
ligand. At present we are in the process of searching for such an IL-18Rα-binding ligand as 
well as the composition of the ligand’s full receptor complex.  
 Strengthening the findings that IL-18Rα is capable of interacting with a ligand other 
than IL-18, Lewis & Dinarello recently showed opposite responses in the rejection of IL-18-/- 
and IL-18Rα-/- pancreatic islets (174), which led the authors to propose the existence of an IL-
18-independent inhibitory pathway that converges with the pro-inflammatory IL-18 signalling 
pathway at the IL-18R. Furthermore, they suggest the involvement of IL-1F7, a member of 
the IL-1 family which binds IL-18 binding protein (IL-18BP) and IL-18Rα thereby inhibiting 
IL-18 activity. Their postulation of an additional inhibitory pathway differs from our 
hypothesis of an alternative, stimulatory ligand. This is probably due to their assessment of 
the roles of IL-18 and its receptor on pancreatic islets in mice that still have an intact immune 
system. Nevertheless, the generation of different phenotypes resulting from deletion of IL-18 
or IL-18Rα is apparent in this model. 
 
IL-18Rα expression in the periphery, but not the CNS, is required for EAE 
One of our goals was to determine the mechanism of action of IL-18Rα activation and 
signalling during EAE. The development of EAE relies upon initial activation of CD4+ T cells 
in the peripheral immune system but the CNS environment is important for reactivating 
infiltrating cells during the effector stages of disease. In contrast to wt and IL-18-/- mice, the 
spinal cord of EAE-resistant IL-18Rα-/- mice is completely devoid of leukocyte infiltration at 
the peak time of clinical EAE (Fig. 5). Furthermore, there was no upregulation of 
inflammatory cytokines and chemokines in the CNS of IL-18Rα-/- mice during peak disease, 
which is characteristic of this time-point and a requirement for ongoing inflammation (Fig. 6). 
However, the lack of IL-18Rα in the CNS does not contribute to these findings and has no 
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role in the pathogenesis of EAE as mice in which IL-18Rα was deleted from the CNS only 
(Wt → IL-18Rα-/-) were not protected from disease (Fig. 8).  
 On the other hand, absence of IL-18Rα from the peripheral immune compartment 
prevents the development of EAE as demonstrated by the resistance of IL-18Rα → wt mice to 
disease induction (Fig. 8). Therefore the presence of IL-18Rα on leukocytes is clearly 
important for the development of EAE. Upon analysis of T cell function, we discovered that 
IL-18Rα-/- lymphocytes are deficient in producing IFNγ in a MOG recall response (Fig. 3c). 
Nevertheless, we speculated that this could not explain the resistance of IL-18Rα-/- mice to 
EAE because mice deficient in or lacking IFNγ, such as IFNγ-/- or IL-12p35-/- mice 
respectively, are usually hyper-susceptible to EAE (96;129;175).  
Activation of MOG-reactive CD4+ T cells results in the upregulation of costimulatory 
molecules and cytokines that are critical for the induction of EAE. During activation, the 
integrins L-selectin and VLA-4 are down- and up-regulated, respectively, which diverts the 
homing of encephalitogenic T cells from the LNs to the CNS. In addition, the levels of T cell 
CD5 expression critically determine the degree of T cell responsiveness. Deletion or block of 
CD5 and VLA-4, respectively, has already been demonstrated to induce EAE resistance in 
mice (159;176). In the case of IL-18Rα deficiency, however, alterations in expression of these 
activation markers did not lead to EAE resistance as there was no difference in their 
expression levels on CD4+ T cells from wt, IL-18-/- and IL-18Rα-/- mice (Fig. 9).  
Finally, EAE resistance of IL-18Rα-/- mice did not result from an increase in the 
number of immunosuppressive regulatory T cells in the LNs, spleen or blood of these animals 
(Fig. 10).  
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IL-18Rα deficiency does not affect leukocyte migration 
The development of EAE in wt mice is dependent on the infiltration of activated CD4+ T cells 
into the CNS, an event that is accompanied by the influx of other immune cells including B 
cells, macrophages and granulocytes (161-163). In fact, we could show that at early time-
points of disease, the CNS is predominantly infiltrated by granulocytes and macrophages 
(Fig. 12b). The activity and migration of granulocytes into the CNS are critical for EAE 
development and disruption of these cells can abrogate the effector phase of EAE (163). We 
tested whether the absence of immune cells in the IL-18Rα-/- CNS was due to a defect in the 
migration properties of granulocytes. However, the in vitro migration of neutrophils from IL-
18Rα-/- mice was identical to that from wt and IL-18-/- mice (Fig. 11). Surprisingly, although 
inflammatory cells are absent from IL-18Rα-/- spinal cords at the peak time of clinical EAE, 
we could show that comparable in vivo granulocyte infiltration occurs in all three groups of 
mice prior to disease onset (Fig. 12b). Interestingly, not only were granulocytes present in the 
IL-18Rα-/- CNS, but similar numbers of other CNS-invading leukocytes, including CD4+ T 
cells, could also be detected at this time-point (Fig. 12a,b). Therefore, IL-18Rα-deficiency 
does not affect the initial migratory properties of leukocytes but their persistence in the CNS.  
 
IL-18Rα deficiency indirectly affects IL-17 production 
The presence of inflammatory infiltrates early on in the IL-18Rα-/- CNS is similar to the 
phenotype observed in IL-23-/- mice (177), whose resistance to EAE likely results from their 
inability to expand and maintain IL-17-producing TH cells (53;56;178;179). Similar to these 
findings, and despite comparable CD4+ T cell infiltration, IL-18Rα-/- mice showed a 
significant decrease in TH17 cells in the CNS on day 7 post-immunisation (Fig. 12c). 
Furthermore, IL-18Rα-/- LN-derived lymphocytes were unable to produce IL-17 in response 
to cognate Ag restimulation, in contrast to wt and IL-18-/- lymphocytes (Fig. 13). Therefore 
the IL-18Rα deficiency affects the production of the novel encephalitogenic cytokine IL-17. 
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Previous data has shown that the expression of IL-18Rα is broadly distributed and not 
confined to NK cells and T cells as previously thought (83-85). By performing experiments 
using BM chimeras, we demonstrated that the loss of IL-18Rα from an accessory cell, and not 
from T or B cells, was responsible for the loss of TH17 cells and for EAE resistance (Fig. 
14a). The importance of IL-18Rα on accessory cells was emphasized by adoptive transfer of 
otherwise encephalitogenic wt T cells that did not induce EAE in IL-18Rα-/- mice (Fig. 14 b). 
Again, this result is similar to IL-12p40-/- mice, which showed decreased severity of EAE 
upon transfer of encephalitogenic wt T cells (145). 
 
IL-18Rα expression on APCs is required for IL-23 production 
The interaction of APCs with T cells and the concomitant generation of costimulatory signals 
and cytokines is an absolute requirement for T cell proliferation and polarisation. Using in 
vitro simulation of either allogeneic or transgenic T cells by IL-18-/- or IL-18Rα-/- BM-DCs, 
we found that T cell activation and expansion are not affected by the loss of IL-18Rα (Fig. 
15a,b,c).  Indeed, adoptively transferred naïve TcR-Tg lymphocytes proliferated to the same 
extent in immunised IL-18Rα-/- hosts as in wt and IL-18-/- ones (Fig. 15d). Normal 
proliferation of T cells coincided with similar expression of costimulatory molecules by wt, 
IL-18-/- and IL-18Rα-/- splenic DCs (Fig. 16a). Despite adequate proliferation, adoptively 
transferred Tg lymphocytes were incapable of upregulating IL-17 production in IL-18Rα-/- 
hosts. These results were similar to those obtained in IL-12p40-/- hosts, but in contrast to wt 
and IL-18-/- mice (Fig. 15e). Finally, we demonstrated that IL-18Rα signalling on APCs is 
critical for the secretion of IL-23p40, but not IL-23p19, and the subsequent maintenance of 
IL-17-secreting T cells (Fig. 17). Our data thus support the hypothesis that IL-17 secretion is 
dependent on the continuous support of TH17-promoting APCs.   
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Conclusion 
Using the animal model of MS, we have provided additional evidence against the TH1 
paradigm of autoimmunity by demonstrating a non-pathogenic role for IL-18. In contrast, 
however, we show that IL-18Rα is essential for the development of EAE, thus implying the 
presence of an alternative IL-18Rα-binding ligand. Furthermore, activation of IL-18Rα is 
necessary for the expansion or survival of TH17 cells in an IL-23-dependent manner. In a 
simplified scheme, the production of the alternative IL-18Rα-binding ligand during Ag 
recognition leads to IL-18Rα signalling, on the surface of an APC, and subsequent IL-23 
release. However, the precise cellular location of IL-18Rα activation during EAE is still 
unknown and a much more complex and indirect pathway possibly exists for its role in IL-17 
production. Nevertheless, the identification of the alternative IL-18Rα-binding ligand could 
provide a potent novel therapeutic approach for the treatment of organ-specific inflammatory 
diseases such as MS. The attractive feature of this IL-18Rα-dependent pathway for 
therapeutic targeting is that its loss does not completely suppress immunity, but rather 
abrogates the development of pathogenic autoimmune effector T cells. 
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